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Poor bioavailability and poor pharmacokinetic characteristics are some of the leading causes of drug development failure. Therefore, poorly-soluble drugs, fragile proteins or nucleic acid products may benefit from their encapsulation in nanosized vehicles, providing enhanced solubilisation, protection against degradation, and increased access to pathological compartments. A key element for the success of drug-loaded nanocarriers (NC) is their ability to either cross biological barriers themselves or allow loaded drugs to traverse them to achieve optimal pharmacological action at pathological sites. Depending on the mode of administration, NC may have to cross different physiological barriers in their journey towards their target.
In this review, the crossing of biological barriers by passive targeting strategies will be presented for intravenous delivery (vascular endothelial lining, particularly for tumour vasculature and blood-brain barrier targeting), oral administration (gastrointestinal lining) and upper airway administration (pulmonary epithelium). For each specific barrier, background information will be provided on the structure and biology of the tissues involved as well as available pathways for nano-objects or loaded drugs (diffusion and convection through fenestration, transcytosis, tight junction crossing, etc.). The determinants of passive targeting − size, shape, surface chemistry, surface patterning of nanovectors − will be discussed in light of current results. Perspectives on each mode of administration will be presented. The focus will be on polymeric nanoparticles and dendrimers although advances in liposome technology will be also reported as they represent the largest body in the drug delivery literature.
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In the domain of drug delivery, 2 ways of targeting are generally differentiated − “passive” and “active” targeting − even if the distinction could be somewhat blurred as we will see later. “Passive targeting” is based on nanocarrier (NC) size and general surface properties, namely, surface charge, degree of hydrophobicity and nonspecific adhesion, which direct them towards particular organs, cross biological barriers, such as specialized epithelia, or enter the cell cytoplasm. On the other hand, “active targeting” refers to specific ligand-receptor recognition or antibody-antigen binding, aimed to increase the selectivity of the drug-carriers delivery. For the purpose of this review, we define “passive targeting” as including general, nonspecific, surface-modified and internal stimuli-responsive NC; excluding any specific ligand recognition. At the present time, most clinical trials involving NC, rely on passive targeting (see www.clinicaltrials.gov (​http:​/​​/​www.clinicaltrials.gov​)), mainly expansion of nanoparticle-albumin-bound drugs (or “nab”) technology, for taxane delivery in cancer and pegylated liposomes (for doxorubicin (DOX) or amphotericin B delivery).
NC can enter the body via the upper airways and the gastrointestinal tract (GIT) respectively or by injection (intravenous (i.v.), subcutaneous, intramuscular). They have to cross different specialized epithelia, either lung or GIT epithelia, to reach the blood compartment, tumoral vascular endothelium or the blood-brain barrier (BBB) to access pathological tissues via the blood circulation. This is not an easy task, even for nanometric objects (1-1,000 nm), and available pathways are limited to epithelium porosity or transcytosis routes. 
Besides size, a common feature of all administration routes is that the biological interface between NC and the biological medium (solid/liquid interface) is a major determinant of NC fate and therapeutic outcomes. In particular, events such as opsonisation, mononuclear phagocytosis system (MPS) uptake, biodistribution (NC localization among organs), interactions with cell membranes and extracellular matrices strongly depend on interface properties. These properties will be determined by surface chemistry, shape and curvature radius, porosity, roughness, fractal dimension and hydrophobicity (as well as specific recognition elements in case of active targeting). Moreover, additional properties depend on biological medium composition (pH, salts, ionic strength, proteins, etc.), charge (zeta potential) and particle aggregation. The interactive forces involved are mainly van der Waals forces, ionic and water solvatation ADDIN EN.CITE  [1]. 
Nowadays, the majority of new molecules present a delivery challenge because of solubility issues, size or sensitivity to degradation and instability. Over the years, a lot of promising actives have seen their development compromised for similar reasons. Other concerns hampering drug development are adverse side-effects and narrow therapeutic indexes. These pharmacodynamic, pharmacokinetic (PK) and solubility challenges have to be addressed to translate positive in vitro results into clinical outcomes. Encapsulation in NC – nanosized structures carrying drug loads – is a solution to modify drug PK and distribution profiles. Encapsulation can help to achieve one or several of these goals, such as increased residence time (by decreasing renal and reticuloendothelial system (RES) clearance), protection from fast degradation by inhibiting metabolic clearance in blood or inside the GIT, reduced side-effects (by suppressing the volume of distribution or by organ targeting), and crossing specific biological barriers to deliver actives to specific areas. Because of very unfavourable physicochemical properties (molecular weight (MW), sensitivity to enzymatic degradation, charge, etc.), some drugs such as DNA or siRNA have to be developed clinically along with associated NC ADDIN EN.CITE  [2]. The choice of nanometer range for drug carriers is justified by the route of administration (injection, inhalation), increased surface-to-volume ratio for release, mucosa-penetration properties, accessibility of pathways to cross either epithelial barriers or cellular membranes. Moreover, minimum size is determined by renal filtration cut-off (for NC aimed at the systemic circulation), while maximum size is limited by extensive phagocytosis of microparticles in the 1-6 µm range and the emboli properties of even bigger microparticles.
All these considerations have led to the development of several NC classes, including liposomes ADDIN EN.CITE  [3], micelles ADDIN EN.CITE  [4], dendrimers  ADDIN EN.CITE  [5] and solid polymeric particles ADDIN EN.CITE  [6, 7], among others (Fig. (1)). While first-generation NC rely on very simple structures (single polymers or excipients) and geometry, NC to date are becoming increasingly sophisticated, incorporating several polymers or materials to impart multiple functions. Indeed, different properties are sought for NC: cytocompatibility, maximization of encapsulation efficiency, elimination and, finally, the ability to cross biological barriers. Moreover, knowledge of the biological determinants of NC fate in vivo is improving, allowing more rational development of their physicochemical properties.

Fig. (1). Different types of Nanocarriers
(A) Micelle: self assembly of amphiphilic molecules; (B) Liposomes vesicles primarily constituted of a phospholipids bilayer along with another types of lipids (cholesterol or PEG-phospholipids conjugates); (C) Dendrimers are branched symmetric polymeric structures constituted by a core and branches (the dendrons); (D) Polymeric nanoparticles are matrix particle in which the drug is dispersed (here symbolized with black dots); (E) Nanocapsules, are constituted by an core (generally hydrophilic containing drugs) enclosed in a thin polymeric wall.

The present review will focus on the challenge of biological barrier crossing upon administration via major routes (i.v., oral and pulmonary) and NC characteristics that are determinants of this goal through passive targeting strategies. The aim is to provide a biological perspective to NC development linked with recent experimental data. Issues regarding carrier fate and elimination will not be covered, and readers are referred to a recent review on this aspect of NC fate in the body ADDIN EN.CITE  [8]. Intracellular delivery and trafficking represent research fields by themselves, and are described in recent reviews ADDIN EN.CITE  [9, 10], although some information will be provided when optimal cellular uptake properties are in conflict with upstream targeting step requirements.

2.	THE I.V. ROUTE
The i.v. route is the fastest, easiest and most reliable route of entry for all drug NC, allowing quick and complete distribution across the body via the systemic circulation. However, even if i.v. injection provides fast distribution in the blood compartment, NC still have to overcome several physical and physiological barriers (Fig. (2)), protecting the body against intruders, to reach targeted organs, such as solid tumors or inflammation sites. The principal obstacles to NC are: 1) Clearance by the RES or MPS; 2) The immune barrier: reaction of the immune system, activation of the complement cascade and allergic responses to foreign materials; 3) Fast renal elimination by glomerular filtration; 4) The blood vessel wall, particularly the endothelial cell (EC) lining and basement membranes, preventing direct access to organs and tissues at the capillary level.
Finally, once NCs have evaded these barriers, they should be able to diffuse in the immediate environment of targeted cells (in the interstitial space) and release their contents efficaciously. In addition, they may have to reach targeted cell membranes for eventual internalization, if the drug needs to be released in cytosol to exert its action. Alternatively, the vascular endothelium has been proposed as a direct target of drug carriers mainly by active targeting to specific receptors expressed on the cell surface ADDIN EN.CITE  [11]. 
An exhaustive presentation of all physiological barriers (Fig. (2)) crossed by NC aimed at tumour sites is beyond the length of this review. Our review on NC surface properties will concentrate on 2 aspects. First, the relationship between surface characteristics and opsonisation will be discussed along with some consequences in terms of MPS uptake and biodistribution. Second, the determinants of efficacious solid tumour passive targeting, and the extravasation (vascular wall crossing) process towards the tumour interstitium will be presented. Readers are referred to recent reviews regarding the specific domain of complement cascade induction by NC surfaces ADDIN EN.CITE  [12], renal filtration, NC fate after MPS uptake  ADDIN EN.CITE  [8] and cell uptake ADDIN EN.CITE  [9].
Fig. (2). General view of biological barriers to i.v. delivery of drug-loaded NC aimed at the solid tumour interstitium

2.1.	The first barrier: NC opsonisation
Opsonisation is a process of protein adsorption occurring on the carrier surface immediately upon injection in biological medium. In blood, different plasma proteins, such as immunoglobulin G (IgG) and IgM, apolipoproteins (Apo), fibronectin, complement system proteins, etc., tend to absorb on NC surfaces ADDIN EN.CITE  [13], forming a “protein corona”  ADDIN EN.CITE  [14]that shapes NC surface properties in biological medium ADDIN EN.CITE  [1]. The corona is a dynamic layer, with variable kinetics of association and dissociation for each protein or surface type. The relative abundance of proteins in plasma or the cell interstitium and their affinity for the surface define this dynamic ADDIN EN.CITE  [15]. Albumin, the major plasma protein (about 55%), tends to bind to NC by hydrophobic and ionic interactions, but with lower affinity than the above-mentioned proteins, and will be eventually displaced. Albumin is considered as a “dysopsonin”, i.e., it promotes longer circulation, probably by binding competition with opsonins ADDIN EN.CITE  [16, 17]. As we will see later, these exchanges influence the carrier’s fate, including NC/cell interactions, elimination, immune reactions and biodistribution, mediated mainly by their effects on MPS uptake.
Macrophages of the MPS, mainly composed of macrophages from the liver (Kupffer cells) and spleen, as well as peripheral macrophages are part of the immune system. Their role is to engulf and destroy foreign particles, such as bacteria and viruses in blood, by phagocytosis ADDIN EN.CITE  [18]. Unfortunately, they also recognize NC as foreign and clear them from blood. This clearance is dependent on opsonisation. Generally, macrophages do not recognize NC directly. They express several opsonin receptors which mediate recognition ADDIN EN.CITE  [13, 18]. Receptors for bacterial and fungal polysaccharides (PS) have been identified, and “scavenger receptors” have been suggested to participate in the uptake of PS particles ADDIN EN.CITE  [19]. Ligand-receptor recognition triggers actin rearrangement and phagosome formation. 
2.1.1.	 Mechanisms of protein binding to NC surfaces
The physicochemical characteristics of NC, such as surface hydrophobicity, surface charge and charge density ADDIN EN.CITE  [20], carrier size ADDIN EN.CITE  [15], and the presence of functional groups influence opsonisation and, consequently, uptake by the MPS. Other biomaterials, such as lipids, could also bind to NC surfaces, although the biological significance of this observation has not yet been determined ADDIN EN.CITE  [21]. Several strategies have been explored to alter NC surface properties, including polymer coverage and charge modification to decrease or change opsonisation patterns to curb MPS uptake, increase circulation time and transform NC biodistribution. Interactions between proteins and NC surfaces are determined mainly by electrostatic, hydrophobic and/or specific interactions, such as ligand-receptor recognition ADDIN EN.CITE  [1]. Generally, the degree of surface hydrophilicity influences the amount and identity of bound proteins. On the other hand, hydrophobic surfaces are opsonised at a higher speed than hydrophilic surfaces ADDIN EN.CITE  [13].
2.1.2.	Surface properties and hydrophilic polymer surface coverage
The incorporation of neutral and hydrophilic polymers onto NC surfaces (absorbed or covalently-linked) increases NC half-life in the systemic circulation (from minutes to hours), and this effect is related to decreased opsonisation.
Pegylation of NC surfaces
In the 90, linear poly(ethylene glycol) (PEG) were introduced in liposomes  ADDIN EN.CITE  [22, 23] and polymeric NP ADDIN EN.CITE  [24]. PEG decreases protein interactions with NC surfaces ADDIN EN.CITE  [25], modifies PK and biodistribution ADDIN EN.CITE  [13], and influences NC cellular uptake ADDIN EN.CITE  [26]. PEG chains of sizes from 2 kilo Dalton (kD) and beyond are able to greatly reduce the adsorption of opsonins and other serum proteins ADDIN EN.CITE  [27, 28]. Hydrophilic and flexible PEG chains act via a steric repulsion effect, rendering protein binding unfavourable. This repulsion effect depends on chain length, optimal surface density and optimal chain configuration ADDIN EN.CITE  [13]. 2 to 5 kD seems to be the minimum length for the “stealth” effect ADDIN EN.CITE  [27, 29], but longer chains have shown improved circulation time for rigid nanocapsules  ADDIN EN.CITE  [30] and changed in vivo biodistribution and clearance ADDIN EN.CITE  [31]. PEG has been added either as an adsorbed layer on NC surfaces (NP made of poly(styrene) (PS) or poly(D,L-lactide-co-gycolide) (PLGA)), or attached covalently to other NC components (phospholipids, polyesters, etc.). Covalently-linked PEGs have gained prominence, as adsorbed polymers on particles hydrophobic surfaces, such as Poloxamer® (triblock of PEG-PPG-PEG), are subjected to shedding by competition with plasma components, particles swelling and erosion, compromising surface repulsive properties and decreasing NC circulation time ADDIN EN.CITE  [32, 33].
Optimal protein resistance has been reported in poly(lactic) (PLA) polymeric NP with 5% w/w PEG content. PEG chain density for optimal conformation and efficacy translates into an inter-chain distance of around 1.5 nm on polyester NP surfaces ADDIN EN.CITE  [27]. This distance is crucial for PEG chain organisation and the prevention of penetration of smaller opsonins between PEG chains.
In the case of liposomes, the percentage of pegylated phospholipids necessary for stealth behavior is about 5-7% mol. with PEG 2 kD and 15-25% with smaller PEG 350 D to 1 kD ADDIN EN.CITE  [33]. Furthermore, lipids with higher transition phase temperature or cholesterol tend to decrease nonspecific binding of opsonins by increasing bilayer stability ADDIN EN.CITE  [34]. The addition of PEG increases the circulation time of liposomes from minutes to hours (up to 24-48 h). It is not clear though if the effect is strictly due to the prevention of opsonisation or mediated through steric stabilisation of the phospholipid bilayer, preventing aggregation and their fast elimination ADDIN EN.CITE  [35].
It is generally accepted that the PEG layer should reach such a density, PEG chains are forced to adopt an intermediate “mushroom/brush” or “brush” configuration as seen in Fig. (3), but without leaving exposed hydrophic or charged surfaces where opsonins can bind ADDIN EN.CITE  [12, 33]. Some conflicting results regarding PEG coverage efficacy are likely due to misuse of the term brush and mushroom configuration and a lack of complete physicochemical characterisation of surfaces. In particular, optimal PEG density may vary with curvature radius and core modulus (from liposomes to hydrogel particles to rigid polymeric NP).  
Linear PEG (usually methoxy-PEG) is the standard, but other configurations have been tested. While branched PEGs are less effective than linear PEGs of equivalent sizes ADDIN EN.CITE  [36], it had been shown that PEG 1400 distearate in PLA NP, forming a hydrophilic loop exposed at the surface and anchored by 2 hydrophobic domains buried in the particle core (Fig. (3) panel C), decreases opsonisation and macrophage uptake ADDIN EN.CITE  [37]. Multiblock copolymers of PLA and PEG have the same “loop” configuration. Some studies have reported similar efficacy with loop configuration  ADDIN EN.CITE  [38] whereas others have demonstrated that, although superior to naked PLA particles in terms of opsonisation and macrophage uptake, multiblock NP have reduced efficacy in preventing protein binding and macrophage uptake compared to NP with PEG “mushroom” configuration ADDIN EN.CITE  [26]. Although overall PEG content was reported to be higher in multiblock NP, PEG surface coverage was lower, as determined by XPS analysis, suggesting a hypothesis to explain the results obtained ADDIN EN.CITE  [26]. 

Fig. (3). PEG NC coverage
(A) “Brush” regimen (high density), (B) “Mushroom” configuration (low density), (C) “PEG loops”: multiblock NP (PLA-PEG-PLA)  ADDIN EN.CITE  [26] or PLA particles with PEG 1400 distearate ADDIN EN.CITE  [37]. PEG chains are presented in black, and the NC core in grey.

A complex interplay between PEG chain length, carrier size (determining surface availability for PEG anchorage) andweight ratio between PEG and hydrophobic components of the carrier (e.g. PLA-PEG particles) is influencing the final surface properties of NC. For instance, for the same PEG molecular ratio, if NC size increases, total NC surface decreases, and curvature radius declines, augmenting PEG coverage and density. It is important to state that, even after optimisation of hydrophilic polymer coverage, opsonisation is not completely abolished, and significant amounts of opsonins are still detected on NC surfaces ADDIN EN.CITE  [27, 39].
PEG and immunity
The question of NC immunity is seldom addressed although some recent results have raised the issue in relation to PEG use. For a long time, PEG was considered as non-immunogenic and to prevent immune recognition of NC. However, antibody development against pegylated liposomes has been observed ADDIN EN.CITE  [40]. Immune reactions to and the toxicity of pegylated liposomes seem to be linked with long-term circulation. A diffusible PEG-lipid molecule in pegylated liposomes has been proposed so that PEG shedding off the surface intervenes with time, rendering NC susceptible to RES clearance and thus limiting circulation time as well as the potential side-effects linked with long-term exposure ADDIN EN.CITE  [41]. Long-circulating pegylated liposomes can also result in complement activation and pseudo-allergic reactions ADDIN EN.CITE  [42], which can be prevented by shielding some specific negative charges ADDIN EN.CITE  [43]. Complement activation has also been reported for polyester/PEG nanocapsules ADDIN EN.CITE  [12], but does not show correlation with surface hydrophobicity, as does opsonisation ADDIN EN.CITE  [44]. 
Surface heterogeneity
Surface heterogeneity is not easily documented but may be the cause of NC under-performance. For instance, patchy or non homogeneous PEG coverage and the existence of a particle subpopulation with suboptimal PEG coverage could accelerate opsonisation and elimination ADDIN EN.CITE  [33]. This surface heterogeneity could be caused by a non-homogenous mix of pegylated ingredients during the preparation stage, leading to different PEG contents. For liposomes, in the presence of divalent cations, the phase separation of pegylated and acidic phospholipids could explain rapid macrophage localization owing to the increased opsonisation of exposed, non-pegylated patches ADDIN EN.CITE  [33]. Heterogeneity can also be found in less dynamic structures, such as PS particles ADDIN EN.CITE  [45]. For solid polymeric NP, the phase separation of polymers with different degrees of hydrophobicity could occur during the solvent removal step.  Atomic force microscopy (AFM) phase imaging studies in tapping mode provide mapping of some surface property variations. Non-homogenous phase imaging of pegylated polyester NP could indicate micro-domain separation and suboptimal coverage of PEG, even for NP, showing protein repulsion properties ADDIN EN.CITE  [26, 46]. Surface heterogeneity is also the consequence of NC degradation, with breakdown or partitioning of PEG conjugates ADDIN EN.CITE  [33].
Other polymers
While PEG remains the most effective polymer, other flexible hydrophilic polymers have been tested, such as different polysaccharides (although they are more prone to immune recognition), dextrans and heparans ADDIN EN.CITE  [25, 47, 48], poly(vinyl alcohol) (PVA), PEG-PVA combination ADDIN EN.CITE  [49], polyvinylpyrolidone (PVP) ADDIN EN.CITE  [50], etc. PVA is also often employed as a stabilizer for the emulsion step during solid polymeric NP preparations. Residual surfactants resulting from preparation conditions could remain bound to the particle surface in non-negligible quantities, influencing surface properties [51]. 
2.1.3.	Surface properties: charges and opsonisation
The nature of charge and charge density on NC can be evaluated by zeta potential, an electrostatic potential present at a shear plane located at a distance from the particle surface. These potential values rely on the nature of the surface material and dispersion medium. Thus, it is not a true intrinsic property of NC as it will depend strongly on the environment: pH, ionic concentration ADDIN EN.CITE  [52], polymer coating, hydrated layer and protein shielding. The nature of charge and charge density  ADDIN EN.CITE  [53] is a determinant of the amount and identity of proteins bound on the NC surfaces ADDIN EN.CITE  [13]. Neutral particles have a slower opsonisation rate than either cationic or anionic surfaces. Zwitterionic or neutral surfaces have been shown to prevent protein adsorption on particle sizes of 3-10 nm (quantum dots). With anionic or cationic surfaces, hydrodynamic diameter increases up to 15 nm because of protein adsorption ADDIN EN.CITE  [54]. The zwitteration of NP silica surfaces reveals comparable results with pegylation in terms of protein binding prevention in in vitro assays ADDIN EN.CITE  [55]. 100 nm PS NP with different zeta potential have been observed to end up with similar zeta potential after serum protein binding. This adsorption also causes a 15- to 25-nm diameter increase ADDIN EN.CITE  [56].
In liposomes (80-100 nm, unknown polydispersity index (PI)), heightened clearance is seen with increased negative charges, concomitant with enhanced uptake by the liver and decreased uptake by the spleen ADDIN EN.CITE  [57]. On the other hand, negatively-charged PEG-PLA micelles (35 nm, PI <0.1) show lower uptake in the liver and spleen than neutral micelles ADDIN EN.CITE  [58]. Stability, broad size distribution and opsonisation could explain these divergent findings.
	As cell membranes are negatively charged, it has been argued that cationic NC interact favourably with them. However, electrostatic interactions between NC and macrophage membrane have been found to differ in vitro and in vivo. This difference could be related to very different opsonisation coatings, during in vitro uptake studies and in vivo distribution experiments ADDIN EN.CITE  [52]. 
Surface charge could play a role in NC toxicity. Positively- and negatively-charged NC, such as poly(amido amine) (PAMAM) dendrimers have been linked with adverse interactions to red blood cell (RBC) membranes, culminating in hematolysis ADDIN EN.CITE  [59]. Hematolysis assays are performed in phosphate-buffered saline (PBS) without plasma proteins interfering in the test. In vivo, however, opsonisation could occur and charge changed, mitigating toxicity  ADDIN EN.CITE [60] or platelet aggregation ADDIN EN.CITE  [61].
2.1.4.	Opsonisation and NC size
Although this review focuses on NC surface properties, NC size is fundamental as it has a profound effect on opsonisation and, thus, on PK, biodistribution, toxicity  ADDIN EN.CITE  [60] and passive targeting (see Section 2.2). Cyanoacrylate particles (80, 170 and 240 nm), with different PEG-derived surfaces, show that serum protein adsorption and phagocytic uptake decrease with smaller diameter and longer PEG chains. The half-life of pegylated carriers is extended about 20-fold and the drug concentration in tumours is increased by about 3-fold. NC of 80 nm take up less proteins than 240-nm NC (about 6-fold less), indicating a role for PEG density coverage and conformation ADDIN EN.CITE  [62]. Curvature radius could be involved in binding efficacy too, as reported for PS NP ADDIN EN.CITE  [15]. NC size seems also to participate in the choice of plasma proteins binding to PS particles ADDIN EN.CITE  [20].
Macrophages are designed to engulf particles in the range of 1-6 µm with maximum efficacy around 2-3 µm ADDIN EN.CITE  [63]. The uptake of opsonised 1-3 µm size PS beads has been demonstrated to proceed by phagocytosis, while smaller 200 to 750 nm beads only partially enter macrophages by phagocytosis, as an endocytosis mechanism is also involved ADDIN EN.CITE  [64]. These results are consistent with data on PLA/PEG NP uptake by murine macrophages, revealing a role for a non-phagocytosis mechanism ADDIN EN.CITE  [26]. 
The filtering effect of RES organs (liver, spleen and kidneys), based on NC size, is a major player in NC biodistribution ADDIN EN.CITE  [8]. Fast clearance by glomerular filtration is observed below 5.5 nm hydrodynamic diameter ADDIN EN.CITE  [54]. Small NC (quantum dots, 5-10 nm diameter) tend to increase their diameter upon opsonisation and, consequently, decrease their renal filtration ADDIN EN.CITE  [54]. NP with a mean diameter of 80-100 nm show prolonged blood residence and a relatively low rate of RES uptake. For instance, the biodistribution of non-pegylated liposomes of different sizes (30-400 nm) in blood, liver, spleen, and tumour indicates that liposomes of 100-200 nm size are mainly located in the circulation while liposomes smaller than 50 nm and larger than 250 are mostly cleared. Regarding organs of the RES/MPS, liposomes of 50 nm and less are captured in the liver (liver fenestrae are about 100 nm), while those of 100-400 nm are only partially captured (plasticity of liposomes allowing spleen escape). On the other hand, the spleen primarily captures the biggest liposomes (400 nm) ADDIN EN.CITE  [65]. 
2.1.5.	Particle shape
The impact of NC shape on clinical performance, such as targeting and MPS uptake, was not studied extensively until recently ADDIN EN.CITE  [66, 67]. Particle shape certainly affects NC behaviour and motion in blood flow, membrane adhesion strength, cell uptake pathways and efficacy ADDIN EN.CITE  [68, 69]. Particle shape impacts phagocytosis by macrophages and, more importantly, particle shape and size impact attachment and internalization separately ADDIN EN.CITE  [70]. Filament-like micelles or “filomicelles” have been compared to spherical micelles in vivo: their half-time in blood is increased about 10-fold in comparison to their spherical counterparts ADDIN EN.CITE  [71]. 
2.1.6.	Conclusion on opsonisation and surface properties
 “Naked” hydrophobic NC are opsonised in minutes, rapidly cleared from the circulation and sequestered in macrophages. They are sequestered mainly in organs of the MPS, the liver and spleen (80% of macrophages), and degraded. This property is advantageous to target these organs passively but complicates the targeting of other organs. It is noteworthy that even stealth NC are opsonised and cleared from the circulation by macrophages, albeit at a slower rate. Eventually, NC degradation by-products will be eliminated via urine or feces. If the ingredients are not degradable, accumulation and toxicity can occur in the liver and spleen ADDIN EN.CITE  [8].
In a nutshell, neutral pegylated NC between 10-100 nm undergo reduced opsonisation and decreased hepatic filtration, which results in long systemic circulation, allowing extravasation and targeting (see below). Clearance by the MPS is not per se a bad thing. A certain level of “stealth” is necessary to ensure that NC are not recognized prematurely by the MPS and degraded. On the other hand, very long circulation could cause unwanted side-effects over time. It is, therefore, necessary to reach equilibrium between stealth and opsonisation as well as between stability and degradability, therapeutic efficacy and biocompatibility.
2.2.	NC extravasation
Having discussed the determinants of NC behaviour in blood after i.v. administration, we will now review the NC properties significant for specific extravasation toward tissues by passive mechanisms. To achieve this goal, we have to consider the structure, organization and heterogeneity of blood vessel walls (arteries and veins of different sizes alike) that are composed of 3 layers or “tunica” as seen in Fig. (4). The thickness of each layer depends on vessel function.

Fig. (4). General organisation of blood vessel walls

The intima, the layer in direct contact with blood flow, is composed of an EC layer supported by a basement layer comprised mainly of a collagen matrix. EC harbour a layer of proteoglycans, called the glycocalyx. The media is composed of smooth muscle cells associated with an elastic matrix of collagen and elastin. These cells are responsible for vasodilatation and vasoconstriction. The adventitia, mainly comprised of a collagen matrix and fibroblasts, contributes to the reinforcement of larger vessels. Unless the target is the blood vessels EC themselves, crossing the vascular wall to reach organs is a very difficult task for NC, even in the smaller arteries or venules 
2.2.1.	Anatomy of normal capillaries
Of the general organisation described above, precapillary arteries, post capillary venules and capillaries themselves, retain only the EC lining with a basement membrane – sometimes incomplete (the “intima”). An incomplete layer of pericytes is encountered, wrapped around EC by longitudinal and lateral extensions. Pericytes (also called mural cells) are contractile cells that act on blood flow and play a role in permeability (for instance, they are in larger number in the BBB where vascular permeability is tightly regulated).  The capillaries are responsible for bringing nutrients and oxygen from the blood towards the cell interstitium and removing cell wastes. Their diameters are 4-15 µm, compared to 6-8 µm for RBC. Exchanges with tissue interstitium are favoured in capillaries by slow blood flow, a large surface area to volume ratio and because of their wall structure detailed below. The total surface of the EC lining is about 7,000 m2 (representing about 6. 1013 cells), underscoring the importance of regulating exchange across this barrier ADDIN EN.CITE  [72]. Normal capillaries are classified according to their organization and sizes of pores and holes in their structure as illustrated in Fig. (5).

Fig. (5). Different types of normal capillaries and transport pathways 
(A) Continuous capillary, (B) Fenestrated capillary, (C) Open fenestrated capillary, (D) Sinusoidal capillary. VVO: vesicular-vacuolar organelles; TE channels: transendothelial channels (adapted and modified from ADDIN EN.CITE  [73])

EC are very flat, asymmetric cells (about 1 µm thick or less). Their luminal surface is exposed to blood flow, and the abluminal surface is exposed to the interstitium. EC of different tissues and organs are morphologically and functionally distinct ADDIN EN.CITE  [72, 74]. They undergo dynamic changes upon activation (during inflammation, for instance) or in pathological conditions (tumoural angiogenesis). Four principal structures are illustrated in Fig. (5). More details on capillary morphology can be found elsewhere ADDIN EN.CITE  [73, 74, 75].
“Continuous walls” are formed in capillaries from skin, muscle, lung and at the BBB. They constitute a continuous lining on the luminal part of the vessels with permeability heterogeneity in organ function. Junctions between cells are overlapping regions (intercellular clefts) sealed by protein structures, the “tight junctions”. EC rest on basement membranes composed of collagen fibrils, laminin, fibronectin, and glycosaminoglycans responsible for additional restrictions to molecule movement. However, intercellular clefts allow some exchange of water and small solutes with limited size of a few nanometers. EC are covered by a proteoglycan layer, the glycocalyx, on the luminal side of the membrane. Moreover, very active vesicle trafficking is observed in EC with a large population of caveolae (60-70 nm) and some transcytosis activity. EC flatness limits the distance for caveolae to travel to transfer their contents from the vessel lumen to the sub-endothelial space (tissue interstitium).
“Fenestrated walls” are constituted of EC with large intracellular pores (50 to 60 nm), with (in exocrine glands and the GIT) or without diaphragm (kidney glomerulus). The presence of the diaphragm seems to reduce permeability to about 5-6 nm sized macromolecules and objects. The basement membrane limits overall permeability. A certain level of transcytosis is also seen but with fewer caveolae and more frequent transendothelial channels (TEC) than in continuous capillaries. Diaphragms of fenestrae and TEC are constituted of proteins arranged in octagonal geometry, including radially-organized fibrils connected to the center of the pores. Their precise role is still unknown.
“Discontinuous, sinusoidal or leaky walls” have large holes (100 to 150 nm) between EC (intercellular gaps), less tight junctions, and discontinuous (spleen, bone marrow) or absent (liver) basal membranes, allowing the passage of large proteins and even cells into the interstitium. 
2.2.2.	Importance of the glycocalyx
As mentioned earlier, this proteoglycan layer, sitting on the luminal/apical surface of EC, is present ubiquitously from capillaries to large arteries, albeit with varying thickness.  It has a crucial function in renal glomerular filtration, as it completely covers the fenestrae, decreasing the molecular cut-off ADDIN EN.CITE  [76]. It likely participates in interactions between EC and NC surfaces. The importance of this structure has been underestimated for a long time, mainly because it is difficult to image in microscopy ADDIN EN.CITE  [77]. It is composed of 2 layers (Fig. (6)). First, the inner layer, an ordered structure extending 40 to 60 nm from the surface, is composed of core proteins and membrane-attached molecules with side-chains up to 100-200 nm. Glycoproteins (such as cellular receptors with short and branched sugar side-chains) and proteoglycans (proteins with long carbohydrate polymers) are molecules belonging to this glycocalyx inner layer. Individual fibres are spaced at a maximum distance of 20-nm apart ADDIN EN.CITE  [75]. This cell-attached layer accounts for hindered diffusion and is an osmotic barrier to plasma proteins (and thus eventually to NC). By regulating protein exchange with the cell interstitium, it controls fluid exchange locally ADDIN EN.CITE  [78]. 
Second, an outer layer (Fig. (6)), appearing as a less ordered and more dynamic structure, extends up to 500 nm from the cell membrane in capillaries (several µm in arteries) with different elements absorbed transiently from blood (polymers, plasma proteins, etc.) or cell secretions (soluble proteoglycans, etc.). Secreted soluble proteoglycans are in equilibrium with blood ADDIN EN.CITE  [79]. This dynamic structure is sensitive to shear stress from blood flow and the enzymatic cleavage of covalently-bound components, and is continuously exposed to shedding and de novo synthesis. It seems to have a role in blood cell flow in microvessels, acting as a lubricant and repulsing erythrocytes from EC membrane interactions ADDIN EN.CITE  [80].  Glycocalyx composition may vary from tissue to tissue and pathological conditions, including tumours.

Fig. (6). Glycocalyx structure
Protein backbones appear in black, and glycans in grey. The cell-bound layer is about 60 nm, 
while the absorbed layer is about 500 nm in capillaries. Glycipans and syndecans are the 2 main families of core protein proteoglycans anchored on the plasma membrane. Proteoglycans are associated with glycoaminoglycans (GAG), primarily heparan sulphate (HS), representing 50-90% of GAG along with chondroitin/dermatan sulphate (CS) and hyaluronic acid chains (HA). More details can be found in  ADDIN EN.CITE [81]

The involvements of this dynamic structure in different vascular functions are increasingly well-understood ADDIN EN.CITE  [81, ADDIN EN.CITE  82]. However, its implication in trans-vascular NC delivery is still unclear. The glycocalyx could represent a supplementary barrier that NC have to cross or elude, to either bind to endothelial membranes (by active targeting of receptors − 20-80 nm high − “buried” in the glycocalyx) or cross the cell monolayer via available pores and holes (passive targeting). It could be a mechanical physical barrier to carrier diffusion, a trap acting via ionic interactions with proteoglycans (HS or CS harbour negative charges), leading to the accumulation or repulsion of cationic or zwitterionic surface NC.
When migrating from main flow towards the EC, NC have to diffuse through this layer. Indeed, it had been demonstrated in vivo that glycocalyx removal by enzymatic degradation increases functionalized carrier binding (with antibodies directed to intercellular adhesion protein 1 (ICAM-1) to the rat femoral vein endothelium ADDIN EN.CITE  [83]. Alternatively, the mesh network could capture NC and accumulate them at specific locations, particularly by ionic interaction. Indeed, it had been reported that gene transfer by cationic liposomes is increased in cells expressing proteoglycans ADDIN EN.CITE  [84]. It has also been postulated that the higher tumoural vascular permeability of pegylated liposomes is due to the repulsive effect of PEG on the glycocalyx barrier, preventing their capture, an effect not seen with “normal” liposomes ADDIN EN.CITE  [85]. 
2.2.3.	Hemodymanic considerations
NC extravasation is conditional on the possibility of lateral drift from main blood flow towards the vessel walls (“margination”), to be either taken up by EC endocytosis or leave capillaries via fenestrations or intercellular gaps. This movement depends on several hemodynamic considerations, including vessel diameter and flow rate. Minimal margination has been described for NP, while microparticles accumulate in higher amounts on the walls of capillary models, seemingly showing preferential localization of NP in the center of flow ADDIN EN.CITE  [61]. If NC stay in the center of the bloodstream along with RBC, there could be 2 consequences. First, NC diffusion towards the wall is in competition with blood convection, and, second, NC have less chance of being directed to smaller vessels at the next bifurcation. Indeed, the outcome of blood “phase separation” is preferential collection of the marginal fluid layer by smaller side branches. This “skimming effect”, well-known for RBC, could in fact limit NC access to the microvascular bed, keeping a substantial part of the NC dose in larger vessels where it is ineffective and eventually eliminated. It has been speculated that NC should be designed to accumulate in the cell-free layer to more easily leave the large vessels. Size, density and shape have been reported to affect these properties ADDIN EN.CITE  [68, 86]. Once in the smaller capillaries (with diameters about 5-30 µm), the situation is different as RBC (7 µm) are squeezed in, with blood flow being slower and less structured. NC size is closer to vessel size, and the probability of collision with the EC lining and glycocalyx is increased. Moreover, in the tumour vasculature, irregular vessel organization and less ordered/turbulent blood flow may increase NC interactions with EC.
2.2.4.	Pathways of NC transport across normal capillaries
In brief, assuming that NC are able to remain in close contact with the EC lining, the pathways available for transportation across normal capillary walls are the following:
-	Transport through the intercellular junction of intercellular clefts.  Macromolecular, paracellular transport is limited to sizes below 1-5 nm (e.g. dendrimers), depending on the tight junction type. Zonula occludens inter-endothelial tight junctions in the BBB are an absolute barrier for macromolecules with openings less than 1 nm (see section on BBB) ADDIN EN.CITE  [75].
-	Transport through intracellular fenestrations. Fenestrations without diaphragms are found only in kidney glomeruli with a cut-off between 40 and 60 nm, but the physiological cut-off is about 6 nm because of glycocalyx presence and podocyte contribution to permeability. Diaphragmed fenestrations in other types of fenestrated walls (GIT, endocrine glands) have a physiological cut-off of about 6-12 nm ADDIN EN.CITE  [75].
-	Transport in discontinuous sinusoidal capillaries. Sinusoidal capillaries occur in some organs: liver, spleen and bone marrow. The pore range in human liver is between 50 and 180 nm, average diameter is 105 nm, and neither the glycocalyx nor the basement membrane limits this opening ADDIN EN.CITE  [75].
-	Transcytosis transport.  All EC are involved in transcytosis while intracellular vesicular trafficking is more intense in continuous capillaries than in fenestrae and sinusoids. The exact mechanisms of transcytosis and their extent are still a controversial subject. In normal, continuous capillary beds, macromolecular entities (>5 nm) can only cross the wall via the transcellular route, either by vesicular transport (caveolae are dominant in EC) or special organelles. Their respective contributions vary with capillary type and, currently, their roles are not fully reconciled with permeability study results. Different organelles seemingly related to transcellular transport functions have been identified by imaging of vascular EC (Fig. (7)):
o	Caveolae are cytoplasmic membrane invaginations of about 60-80 nm present at a high rate in EC of continuous capillaries (up to 50-70% of the cell surface in vivo ADDIN EN.CITE  [73]. This endocytosis pathway depends on protein caveolin-1 and specific membrane domains (lipid raft). Caveolae, on their luminal front, take up the bulk of plasma and molecules attached to lipid microdomains. After endocytosis, intracellular caveolar trafficking leads to endosome and exocytosis on the abluminal side (transcytosis). The caveolae pathway can bypass lysosomes. Caveolae can transcytose antibodies  ADDIN EN.CITE  [87] and other blood components across EC into the organ interstitium. Uptake can be mediated by receptor (as for albumin or LDL) or non-receptor-mediated endocytosis (nonspecific, in which ionic interactions at the membrane could play a role. Still, the basement membrane could limit the diffusion of macromolecules and NC after transcytosis. Caveolae are able to transport several types of NC across EC. Although this transport has been shown to be highly dependant on NC size ADDIN EN.CITE  [88], its machinery is still not completely understood ADDIN EN.CITE  [89].
o	Vesicular-vacuolar organelles (VVO) are present in normal post-capillary vessels and in tumoural capillaries as caveolae-like clusters that can span the entire thickness of EC. It is not clear whether VVO are clusters of caveolae (mean diameter around 110 nm), separated by open stromata and diaphragm structures, or are genuine new organelles. Although VVO have been demonstrated to contribute to the transport of macromolecular tracers with sizes up to 11 nm ADDIN EN.CITE  [90], their contribution to vascular permeability has not been completely elucidated ADDIN EN.CITE  [73].
o	Transendothelial channels (TEC) are true, permanent pores (diameter similar to caveolae) in fenestrae endothelium with diaphragm ADDIN EN.CITE  [74].

Other endocytic pathways, albeit present as clathrin-mediated endocytosis, seem to be marginal for transcytosis in EC ADDIN EN.CITE  [73]. The glycocalyx contributes to the provision of negative charges to EC membranes. These negative charges are associated with clathrin-coated membranes. Cationic molecules are preferentially transported by this pathway leading to lysosomes. Anionic molecules (including plasma proteins) are excluded from it, being transported mainly via the fluid phase caveolae pathway and shuttled to the interstitium (via a non-degradative pathway) ADDIN EN.CITE  [91]. Despite a growing body of information, the involvement of transcytosis in passive and active targeting of drug-loaded NC is still under scrutiny. It is a possible pathway, as demonstrated by several studies, but what is the dominant mechanism of transport across the vascular bed? Quantitatively, which mechanism could meet the challenge of delivering a therapeutic level of drug to the tumour interstitium? These questions remain to be investigated.
Although transcytosis occurs predominantly via the fluid phase, albumin, for instance, can bind to albumin receptor gp60 present in lipid rafts and is transported to the interstitium by the caveolae pathway. This property is thought to be a key element in the efficacy of Abraxane®, a paclitaxel albumin-bound anticancer agent, by increasing  its concentration in the tumour interstitium ADDIN EN.CITE  [92]. However, Abraxane® competes with a high concentration of natural albumin (35-55 g/l), and a leaky tumoural vasculature (and the enhanced permeability and retention (EPR) effect) could exert a role too in vascular permeability.
Blood vessels in the vicinity of capillaries could also be involved in vascular permeability to NC. Pre-capillary arterioles are completely surrounded by a layer of smooth muscle cells, with its matrix layer (“media”) decreasing the vascular permeability. Post-capillary venules, on the other hand, are less organized, and NC extravasation typically occurs there, as fenestration density and pinocytosis increase from arteries to post-capillary venules ADDIN EN.CITE  [93].

Fig. (7). Vascular permeability at the normal continuous capillary level
MP: Macropinosis; CLME: Clathrin-mediated endocytosis; CVME: Caveolae-mediated endocytosis; NCNC: Non-clathrin, non-caveolae pathway; TE: Transendothelial channel; VVO: Vesicular-vacuolar organelle; Lys.: Lysosome; End.: Endosome; Ex. : Exocytosis

2.3.	Tumour microvasculature structure: targeting and crossing
Healthy, normal, continuous capillaries do not allow important extravasation of NC, with sizes above 6 nm. However, in pathological conditions, such as tumours or inflammation, capillary anatomy and permeability change. In regard to normal vasculature structure, tumour blood vessels have distinctive characteristics which could be of interest when designing NC. Solid tumours above the size of 2 mm3 initiate angiogenesis to respond to the increased metabolic needs of rapidly-dividing cells ADDIN EN.CITE  [94]. One of the main angiogenesis promoters, vascular endothelial growth factor (VEGF), has been associated with increased vascular permeability as a result of intercellular gap openings and fenestrae induction ADDIN EN.CITE  [95]. The tumoural neovasculature is often not fully mature, resulting in a tortuous network, irregular vessel diameters, and abnormally-branched architecture. Tumour vascular growth patterns also culminate in an usually highly vascularised border, while the inside is deficient in vascularisation or is avascular ADDIN EN.CITE  [94, 96].
In particular, deficiency can be observed in pericytes, smooth muscle cells and abnormal basement membranes (thinner or thicker than usual), all elements participating to the stabilization of newly-formed vessels. The resulting tumoural capillaries are characterized by leaky and enhanced permeability with intercellular gaps (mean size of about 1.7 µm)  ADDIN EN.CITE  [97]and transcellular porosity up to 100-780 nm ADDIN EN.CITE  [98], compared to a few nm for normal, continuous capillaries. Moreover, increases in fenestrae ADDIN EN.CITE  [98], VVO  ADDIN EN.CITE  [90] and transendothelial channels are observed ADDIN EN.CITE  [97], but variations are seen among different tumour types ADDIN EN.CITE  [99]. The filtration cut-off of tumour vascular permeability is reported to be around 400 to 600 nm in most models  ADDIN EN.CITE  [100] but may vary slightly, depending on tumour type ADDIN EN.CITE  [101]. This high cut-off could be attributed to intercellular gaps rather than transcellular pathways limited to 60 to 120 nm organelles, even if physiological permeability of fenestration is increased in the absence of continuous basement membranes. It is noteworthy that fenestration seems to be linked with negative charges imparted by HS ADDIN EN.CITE  [98]. 
2.3.1.	Passive targeting of tumours by the EPR effect
These leaky characteristics allow “passive” tumour targeting based on the enhanced EPR effect, which was formally conceptualized in 1986 by Matsumura and Maeda  ADDIN EN.CITE  [102] and schematized in Fig. (8). It refers to preferential accumulation of macromolecules in tumoural compared to normal tissues. The accumulation takes place in the tumour interstitium, the extracellular compartment between the basement membrane of capillaries and cells (tumour cells, stroma cells, etc.). The effect is recorded for macromolecules above 40 kD or objects with an hydrodynamic radius from a few nm to around 1 µm. At the basis of this preferential accumulation are high tumoural vascular permeability, slow venous return from tumour tissues and diminished lymphatic drainage ADDIN EN.CITE  [103]. The effect has been recognized for many drug carriers with sizes above renal filtration (6 nm): polymeric NP ADDIN EN.CITE  [104], liposomes  ADDIN EN.CITE  [105] and micelles ADDIN EN.CITE  [4]. Smaller molecules accumulate faster in tumour sites but larger molecules stay for a longer period of time. NC extravasation and accumulation in the interstitium seem optimal for sizes 20-200 nm. The magnitude of the EPR effect on NC or drug accumulation is variable, but rarely over 10% of the initial dose. Most of the dose is still found in the liver and spleen ADDIN EN.CITE  [106, 107]. Tumour tissues show a 4-fold increase in capture for non-pegylated liposomes of sizes between 100 and 200 nm compared to liposomes smaller than 50 nm or larger than 300 nm ADDIN EN.CITE  [65].

Fig. (8). Simplified view of the EPR effect
On the left: situation of normal tissue with continuous capillaries, normal lymphatic drainage, normal ECM and cell organization. NC are excluded from interstitium. On the right: solid tumour with leaky capillaries, increased ECM, defective lymphatic drainage and increased IFP. NC are transported by convection and/or diffusing in the tumour interstitium, accumulating mainly in the perivascular region.  

Preferential accumulation in tumours is also the result of a combination of increased circulation time  ADDIN EN.CITE [106] and enhanced vascular permeability. The increment in circulation time gives more time to the slow extravasation process as the maximum is reached after several hours (usually >24 h). That is why “long-circulating NC” are crucial for the EPR effect. To increase the extent of the EPR effect, to overcome tumour vasculature heterogeneity that limits efficacy, different strategies have been tested, including administration of the pro-inflammatory bradykinin, generating systemic hypertension with angiotensin II (increased blood flow in tumours) or vasodilatation with nitric oxide generators, such as nitroglycerine ADDIN EN.CITE  [96, 108].
2.3.2.	The EPR effect and inflammation
Similar observations on increased vascular permeability and the EPR effect have been reported in inflammation. Indeed, the hallmark of inflammation is increased vascular permeability leading to the escape of protein-rich fluid (exudate) into extravascular tissue. Rheumatoid arthritis (RA), for instance, similarly to tumour development, is characterized by a leaky vasculature and angiogenesis. In an attempt to improve RA management, a glucocorticoid has been encapsulated in small liposomes. This drug, which undergoes rapid clearance, a large volume of distribution and induces side-effects, is a good candidate for encapsulation. The liposomal formulation shows a decrease in distribution volume and diminution of the drug clearance rate. Clinical improvements are attributed to the 7-fold increase of drug concentration in injured joints ADDIN EN.CITE  [109], although it represents only a small percentage of the initial dose. Similar data have been obtained with betamethasone encapsulated in PLGA/PLA-PEG stealth NP in a rat arthritis model ADDIN EN.CITE  [110]. Non-pegylated liposomes have been found to accumulate in the chronically ischemic myocardium and intestine ADDIN EN.CITE  [111].
2.3.3.	Limits of the EPR effect on passive NC targeting
As pointed out by R.K. Jain in a recent review, approved NC (liposomes, albumin NP), to date, show modest clinical improvement ADDIN EN.CITE  [93]. Although the EPR effect is claimed to be at the basis of increased therapeutic efficacy of DOX pegylated lipsome formulations (marketed as Doxil® or Caelyx®) against several cancers ADDIN EN.CITE  [105], some nuances are warranted as improved PK and biodistribution could explain, at least in part, the observed improvements and cannot be ruled out. The 3- to 10-fold increase in tumour accumulation, observed in most studies of this type ADDIN EN.CITE  [33], represent about 1 to 7% of the initial dose. Several hypotheses have been proposed to explain the modest improvements in clinical outcomes, relying on the biology of the tumour environment, and should guide future improvements in NC properties.
Uneven distribution of blood vessels, permeability and blood flow
Because of abnormal angiogenesis in tumours, vascularization and blood flow are not homogenous across tumours, resulting in a non-uniform EPR effect. Some regions of the tumour are inaccessible to NC, causing uneven drug distribution and accumulation of limited quantities of the initial dose (an increase in drug quantity is seen but the accumulated percentage of the initial dose stays low). Window chamber (intravital microscopy) studies have shown an heterogeneous extravasation pattern of 90 nm pegylated liposomes in a tumour model, demonstrating variations in permeability of the tumour vasculature. However, tumour permeability to pegylated liposomes increases 3- to 4-fold in comparison to normal liposomes ADDIN EN.CITE  [85, 112]. Vessel heterogeneity could arise, for instance, from variable pericyte coverage, from 10-20% in glioblastomas to 60% in colon and mammary gland tumours, influencing vessel permeability. Moreover, mature (non-proliferating) vessels with different permeability status, are a non-negligible part of tumoural vessels ADDIN EN.CITE  [101]. Heterogeneity in dose delivery could also derive from tumoural vessels with high or low blood flow ADDIN EN.CITE  [94].
Pressure differences between blood and interstitium
Exchanges are partially driven by balanced tissue perfusion, with fluids coming from blood and returning to capillaries (85%) and lymph (15%). Tissue perfusion is the consequence of hydrostatic and oncotic pressures. Hydrostatic and osmotic pressures are major determinants of exchange across capillaries. They are important considerations for exchange with the interstitium through capillary walls, particularly for NC displaced more efficaciously by liquid convection rather than diffusion though the leaky vasculature of fenestrae.
In tumours, the situation is different from normal capillaries as tumour capillaries are leaky, allowing the movement of plasma proteins and macromolecules into the interstitium ADDIN EN.CITE  [113]. Oncotic pressures increase in interstitial fluid, decreasing the convective transport of macromolecules by liquid movement (the oncotic pressure difference between the vascular and extravascular compartments tends to 0). Moreover, an increase is observed in interstitial fluid hydrostatic pressure (IFP) due to ECM alterations  ADDIN EN.CITE  [101] and because lymphatic drainage is defective. IFP can go from 0-1 up to 50 mm Hg in some tumours ADDIN EN.CITE  [99]. With the oncotic pressure becoming null and the difference between capillary hydrostatic pressure (17-25 mm Hg) and IFP becoming smaller in tumours, convection flux across intercellular gaps is limited ADDIN EN.CITE  [114]. The consequence is a decrease in extravasation as diffusive transport becomes predominant, relying solely on a concentration gradient between blood and the tumour interstitium. Limited NC diffusion in the interstitium determines predominant NC accumulation in the perivascular region, decreasing extravasation even more by diffusion. 
IFP not only decreases NC uptake but also affects their homogenous distribution inside tumours. Indeed, IFP varies from the tumour center to the periphery, generating outward flow from the tumour center to the periphery ADDIN EN.CITE  [93, 101], opposing convective NC transport and potentially washing out NC into peripheral tissues.  
Finally, as pointed out by several authors, the results of tumour targeting by the EPR effect in animal models should be interpreted with prudence. Indeed, it had been reported that in human tumour xenografts, vascular permeability depends on the tumour implantation site, varying with time and treatment course, making NC performance extrapolation. from animal to clinical studies uneasy ADDIN EN.CITE  [93, 94].
The ECM limits NC movement inside the tumour interstitium
After crossing the vascular endothelial barrier, the NC journey towards their target is not yet over. Immediate release of the drug load too close from the blood vessels’ leaky walls may not exert maximal efficacy. The tumour interstitium, albeit an aqueous compartment, is filled with a relatively stiff and partially cross-linked extracellular matrix (ECM) of high collagen content along with proteoglycans and hyalurans and similar to hydrogel, to which cells are attached ADDIN EN.CITE  [113]. The tumoural interstitium has usually higher content in ECM that normal tissues ADDIN EN.CITE  [115].  The ECM presence in the tumour interstitium results in slow diffusion, partly attributed to the sieving effect and interactions primarily with collagen fibers ADDIN EN.CITE  [116]. NC diffusion is not homogenous and depends on the orientation of fibres in collagenous tissues ADDIN EN.CITE  [117]. Moreover, neutral particles may diffuse faster in the ECM than charged particles, even if cationic surfaces are advantageous for initial tumour vasculature targeting ADDIN EN.CITE  [118]. 
Although relatively large NC, e.g., Doxil®/Caelyx® (100 nm liposomes), are extravasated efficaciously by the EPR effect, their further diffusive transport is limited by their size and by the characteristics of the interstitial medium. Diffusion speed depends strongly on MW and size. The dependence of tumour penetration on MW has been studied with dextrans linked to a fluorescent marker. It revealed an inverse relationship between the size of linear macromolecules, vascular permeability and tumour penetration ADDIN EN.CITE  [119]. The results disclosed tumour penetration of 35 µm for 3-10 kD dextrans, 15 µm for 40-70 kD dextrans, and only 5 µm for 2,000 kD dextrans. 40-70 kD dextrans had the highest accumulation compared to smaller dextrans which were able to diffuse in and out easily but with faster clearance. The diffusion of pegylated, spherical gold NP within tumours beyond the perivascular region was also highly dependent on their size, with NP around 100 nm appearing to stay near the vasculature, while smaller NP (10 nm) were rapidly diffused throughout the tumour matrix ADDIN EN.CITE  [29]. Similar results were obtained with polymeric micelles of 25 and 60 nm, respectively ADDIN EN.CITE  [120]. 
NC size in biological medium
If sizes of 50 to 100 nm seem optimal for extravasation, once embedded in biological medium, NC could experience some changes, with a size increase above this threshold. For instance, cation surface adsorption on polyester particles (with negative zeta potential) decreases repulsive forces, resulting in aggregation. Besides opsonisation, naked liposomes are also more prone to aggregation than pegylated liposomes. The size increase in biological medium could explain, in part, their reduced access to the tumour interstitium ADDIN EN.CITE  [85]. NC size and size distribution in biological medium are seldom reported but are fundamental properties. Mayer et al. observed important size variations of PS NP measured in PBS or in complete culture medium, resulting from opsonisation/aggregation phenomena ADDIN EN.CITE  [60]. To prevent this from happening, the role of PEG and that of surface charge in maintaining  the dispersion state of colloids should be considered ADDIN EN.CITE  [121]. Opsonisation as well as swelling (by water uptake) could also affect NC size and size distribution. NC size distribution is not always considered as it should, so that conflicting data and ambiguity arise from a lack of information. In case of broad or polydisperse preparations, it is not always possible to identify the NC size fraction responsible for positive or negative outcomes ADDIN EN.CITE  [122]. 
2.3.4.	Conclusion on the EPR effect and NC properties
Although some nuances on the efficacy of the EPR effect are in order, it is so far the best targeting strategy available, but, as discussed above, its extent is limited by several factors. Regarding drug concentration, the effect is limited to some percent of the dose increase; more than 5-10% of the initial dose is seldom found in the tumour site, the rest (90-95%) being still accumulated significantly in other organs (primarily the liver and spleen) or excreted ADDIN EN.CITE  [107]. There are some indications that clinical improvements are at least partially due to accumulation in targeted tissues, but the effect of slow release from long-circulating NC cannot be ruled out ADDIN EN.CITE  [33]. Some authors are looking for ways to generate a more extensive EPR effect, by increasing nonspecific tumour tropism (such as charge), modifying vascular permeability, interstitial and blood pressures. To fully exploit the EPR effect, a better understanding of diverse tumour environments and tumour capillary functions is needed.
2.3.5.	Passive targeting by surface charge modification
Aside from the addition of hydrophilic polymers (discussed earlier) and ligands ("active targeting", which is beyond the scope of this review), surface charge seems to be involved in “nonspecific” targeting although conflicting results have been reported.  Positive charges are thought to generally influence NC adhesion to negatively-charged cell membranes. Cationic liposomes (150±40 nm) have higher uptake in tumoural areas compared to neutral or negatively-charged liposomes, with selectivity towards the tumour vasculature ADDIN EN.CITE  [123]. It has been proposed that anionic phospholipids are markers of tumoural cell membranes, resulting in increased charge density relative to normal tissues ADDIN EN.CITE  [124]. However, the effect is quantitative rather than qualitative as negative charges are also found in the normal vasculature ADDIN EN.CITE  [125]. Moreover, heightened uptake in the liver and augmented in vivo clearance, that could be attributed in part to opsonisation, drastically reduce blood residence time (half-life as low as 5 min) and increase side-effects ADDIN EN.CITE  [126]. To prevent these effects, the addition of PEG coverage to shield cationic charges has been proposed ADDIN EN.CITE  [127, 128]. The length and density of PEG anchored on the surface seem to be determinants that retain the dual properties of tumour vascular targeting and stealth behaviour. PEG coating adds a hydrated layer on the surface, leading to an apparent decrease in charge (i.e. measured zeta potential). In contrast to these results, a study of NP made of chitosan derivatives, grafting polymerization of methyl methacrylate with different zeta potentials and sizes, showed that negatively-charged NP around 150 nm accumulated preferentially in tumours and less in the liver and spleen than cationic NP ADDIN EN.CITE  [129]. PLGA NP (100±39 nm), surface modified with a cationic compound, displayed a 10-fold increment in binding to arterial walls in in vivo studies compared to unmodified anionic PLGA particles ADDIN EN.CITE  [130]. In blood, cationic carrier surfaces are opsonised (whether PEG is present or not). Possible direct interactions of cationic charges with the anionic EC glycocalyx, possibly explaining tumour vasculature tropism, are thus unlikely. Interaction of the tumour vasculature with cationic NC may be mediated by one of the opsonins with specificity for cationic surfaces ADDIN EN.CITE  [128]. This phenomenon has also been documented with ApoE exchange between circulating VLDL, chylomicrons and NC, conferring hepatocyte tropism to otherwise untargeted NC ADDIN EN.CITE  [61, 131]. Serda et al. reported that cationic surface-modified silicone microparticles favoured their uptake by EC, while anionic alteration favoured macrophage uptake. Whatever the surface charge was before injection, all NP were negatively charged after opsonisation. The uptake results could only be explained by different proteins binding to different charged NP surfaces, changing their cell tropism ADDIN EN.CITE  [132]. In contrast, modifying the profile of adsorbed proteins on NC does not affect the level of EC association in vitro; thus, it seems that cellular association does not depend on the identity of adsorbed proteins and they are consequently not mediated by binding to specific receptors ADDIN EN.CITE  [56]. Roser et al. observed no difference in the in vivo biodistribution of differently-charged NP while in vitro macrophage uptake changed with charge ADDIN EN.CITE  [52]. 
Charges are also important to control NC aggregation, which could change NC biodistribution. DOX silica NC coated with PEG and poly(ethyleneimine) (PEI) showed increased efficacy in an animal model. The authors attributed the improvement in EPR accumulation to controlled size of the silica core (50 nm), the presence of a copolymer layer with PEG (5 kD) and low MW, low-toxicity PEI (1.2 kD) conferring positive charges to the final NP, preventing their aggregation and thus exclusion from the tumour interstitium ADDIN EN.CITE  [121]. Similarly, thiolated pegylated gelatine NP also showed slightly increased accumulation in tumours compared to control pegylated gelatine NP ADDIN EN.CITE  [133].
The effect of charge on targeting should be interpreted cautiously as it is strongly dependent on dispersion media, pH ionic strength as well as proteins or biological surfactant adsorption (see Section 2.1.2). The latter elements could impart their own charges to NC to the surface after adsorption. If confirmed, these results move towards a limited role of surface charge in biological media, being limited to affect preferential binding to NC surfaces of different sub-sets of opsonins.
2.3.6.	Passive targeting with stimuli-sensitive NC
A last strategy to maximize the passive targeting effect is the addition of internal stimuli-responsive properties to NC. Adding stimuli-responsive properties to NC can have different objectives, including triggering drug release in specific pathological environments (and not in normal tissues); changing surface properties for sequestration in a particular site ADDIN EN.CITE  [134]. All these approaches rely on a strong EPR effect to accumulate NC in the tumour interstitium in the first place, before triggering specific release of the encapsulated active, the release of a second targeting device, or a change in surface properties.
Thermal targeting of tumours
Thermal targeting relies on thermally-responsive polymers coupled with localized heating of tumours (internal or external stimuli) to achieve targeted drug delivery ADDIN EN.CITE  [135, 136]. Several strategies have been proposed. Among them, pegylated liposomes, prepared with phospholipids with phase transition (gel to liquid crystal) temperatures around 39-40oC, are destabilized by local, mild hyperthermia induced in a matter of seconds and release their contents ADDIN EN.CITE  [137]. Moreover, thermal treatment by itself has been shown to increase tumour vasculature permeability to liposomes. Another approach relies on the adhesion properties of NC. Micronized aggregates of an elastin-like polypeptide (ELP) were targeted to solid tumours. The aggregates adhered to the tumour vasculature when the tumours were heated to 41.5oC. They dissolved at normal body temperature, increasing the vascular concentration locally, driving ELP across tumour capillaries and augmenting its extravascular accumulation ADDIN EN.CITE  [138].Similar results were obtained with p(NIPAAm)-based material ADDIN EN.CITE  [139], but ELP has the advantage of being a biocompatible macromolecule. 
Tumor interstitium targeting with pH-responsive devices
pH-responsive NP and liposomes have been reviewed recently ADDIN EN.CITE  [135, 140]. Only some characteristic examples will be mentioned here and some limitations discussed. Pathological tissues tend to have a more acidic environment (pH 6.5 to 7.2) than normal tissues (pH 7.4), particularly tumours, because of lactate production and hypoxia. The concept of pH-responsive NC is based on the insertion of a molecule or polymer chain having an acid group with adequate pKa. Protonation in an acidic environment changes ionization status; if the acidic group is strategically located, the molecule undergoes pH-dependent conformation transition, and destabilization of the internal NC structure occurs eventually, either releasing the encapsulated drug or changing surface properties. 
Drug release at the site of action
Liposomes and micelles have been studied extensively to implement different pH-responsive strategies. The first pH-sensitive liposome was composed of dioleoylphosphatidylethanolamine associated with an acidic amphiphile for stabilization. Increasing pH neutralized the amphiphile charge, inducing collapse of the bilayer ADDIN EN.CITE  [141]. Another approach is the addition of a pH-responsive polymer in the phospholipid bilayer. A copolymer of N-isopropylacrylamide, methacrylic acid and N-vinyl-2-pyrrolidone has been proposed for specific anticancer drug delivery ADDIN EN.CITE  [142]. However, adding PEG to the construct to increase its circulation time decreased sensitivity of the system to pH change ADDIN EN.CITE  [143].
PEG can be linked to phospholipids by an acid-sensitive cleavable bond. When the PEG chain, stabilizing liposomes, is cleaved, the liposomes are destabilized and their contents are released ADDIN EN.CITE  [144]. Specific drug release in response to pH has been proposed with NP swelling ADDIN EN.CITE  [145], pH-dependent conformation transition of dendrimers or the release of covalently-linked drug moieties ADDIN EN.CITE  [5, 146], destabilisation of micelles or drug conjugates with sensitive linkage to pH ADDIN EN.CITE  [140]. Other carriers have been designed to be sensitive to endosome pH to escape lysosomal degradation and release their intact contents in the cytosol ADDIN EN.CITE  [147]. We will not, however, discuss this aspect in detail, and readers are referred to the reviews mentioned above. 
Surface modification
Another strategy proposed was to enhance NP retention in tumours by changing their surface charge in response to acidic pH ADDIN EN.CITE  [148]. Stealth NP were prepared by the layer-by-layer technique with alternate layers of oppositely- charged polyelectrolytes, the outer layer being a PEG-conjugated polymer. The outer layer of PEG was shed by pH change, when NC entered the tumoural interstitium, exposing a layer of cationic poly(lysine), with the aim of improving tumour cell uptake ADDIN EN.CITE  [149]. There is another reason for discarding the PEG layer as lower cellular uptake is reported for pegylated devices ADDIN EN.CITE  [150].
Limitations
p(NIPAM) and several other chemicals deployed in several of these studies, although they permit elegant approaches to the problem, are not degradable and/or produce degradation by-products not accurate for long-term administration. It is one of the major limitations for human use. Moreover, the efficacy of the system relies on sharp changes in pH when in vivo, changes are more gradual. Several hypothesis could explain the suboptimal results, one of them being the fact that most of the NC load stays at the periphery of the tumour, where pH is closer to blood pH (less acidic) ADDIN EN.CITE  [141, 151], the lower pH being recorded at the tumour center ADDIN EN.CITE  [152].
Passive targeting with redox-responsive NC
Tumor interstitium are also highly reducing environments with extracellular glutathione concentration about 4-fold higher than in the normal interstitium. The intracelluar glutathione level is even higher: 100 to 1,000-fold higher than the extracellular normal level ADDIN EN.CITE  [141]. Thiol ester and disulfide-mediated redox-responsive NC have been reviewed recently ADDIN EN.CITE  [134, 141]. A good example of this potential approach is the exploitation of disulfide links between the hydrophobic and hydrophilic moieties. For instance, detachable PEG in the presence of glutathione elicits link reduction, breakage, PEG release from the NC surface, liposome destabilization and content release ADDIN EN.CITE  [141]. Alternatively, PEG removal taking place in the tumour interstitium could lead to exposure of specific ligands (the cell-penetrating peptide TAT), improving liposome uptake by tumour cells ADDIN EN.CITE  [153].
Enzyme-responsive NC
The enzyme-responsive NC described so far are primarily based on protease-cleavable polymers as substrates for matrix metalloprotease (MMP) present in higher concentrations in the tumour interstitium. This approach has been taken to remove protease-cleavable PEG to destabilize liposomes ADDIN EN.CITE  [150, 154], remove cleavable poly-anionic peptides, neutralize cationic domains on quantum dots to improve their cellular uptake ADDIN EN.CITE  [155], and unveil specific ligands after NC extravasation. In this last example, MMP-2 up-regulated in angiogenesis cleaves PEG connected to NC by a short peptide-specific substrate. The MMP-2 action removes PEG, uncovering specific targeting ligands ADDIN EN.CITE  [156, 157]. 100-nm pegylated gelatin NP can accumulate significantly in the tumour interstitium. Under enzymatic MMP-2 and MMP-9 activity, gelatine (a collagen derivative) hydrolysis releases 10-nm model NP (quantum dots) in the interstitium with better diffusion capabilities ADDIN EN.CITE  [158]. This approach could potentially address concerns about limited diffusion of carriers into the tumour interstitium.

3.	THE BBB
3.1.	Concept and main functions
	The BBB, or hematoencephalic barrier, is a sub-type of continuous capillaries (Fig. (5)), with a very specific physiological structure (Fig. (9)) that separates the bloodstream and the central nervous system (CNS). The main function of the BBB is to support brain homeostasis because of its high sensitivity, vulnerability and great need for oxygen and nutrients. Thus, the BBB is a very selective biological filter that facilitates the supply process and waste elimination. At the same time, it protects the CNS from different agents circulating in blood: pathogenic microorganisms, toxins, hormones and other substances capable of changing the internal environment of the brain, including fluctuations of pH or potassium concentration ADDIN EN.CITE  [159, 160]. It should be noted that the CNS is also protected from the immune system (antibodies and leukocytes), which considers the brain tissue as foreign ADDIN EN.CITE  [161]. Consequently, changes in BBB functioning can cause functional disorders or diseases of the CNS ADDIN EN.CITE  [160]. On the other hand, its protective function, including the enzymatic activity of BBB cells ADDIN EN.CITE  [162], complicates the treatment of many neurological diseases, because many active molecules cannot cross this obstacle ADDIN EN.CITE  [163, 164]. Thus, research on how to overcome the BBB to enhance drug delivery is quite current. 
3.2.	Structure
	In general, the BBB includes the basement lamina and 3 cell types: EC, pericytes and astrocytes (Fig. (9)) which are connected differently to each other according to their type (see below).

Fig. (9). General structure of the blood brain barrier.
(1) Basement membrane, (2) Endothelial cell (EC), (3) pericyte, (4) astrocytic projection, (5) tight junction, (6) cell nucleus.
	The basement membrane is a protein film, the thickness of which varies from 40 to 50 nm. It completely surrounds EC and pericytes on the side of the brain and so separates them partially from each other and completely from astrocytic projections (also called astrocytic end-feet) and brain extracellular fluid. Many studies have shown that the basement lamina contributes to the restricted passage of proteins and is thus protective ADDIN EN.CITE  [165, 166]. Nevertheless, excellent BBB selectivity is mainly explained by the exceptional properties of the capillary EC layer, particularly by their organization and internal structure. The distinctive feature of blood vessels of the CNS is the absence of fenestrations and intercellular gaps between EC, which are interconnected by tight junctions that restrict extracellular diffusion of any relatively large objects through the capillaries. The tight junctions provide not only cell adhesion, but also the possibility of regulating junction permeability, depending on the biochemical environment [167]. In addition, tightness of the capillaries can be characterized by their electrical resistance. In rats, the resistance value of muscle capillaries is only about 30 Ω⋅cm² while that of the brain rises to about 2,000 Ω⋅cm² ADDIN EN.CITE  [168]. It should be noted that the barrier functions exercised by EC of the BBB are also explained by their specific histological and biochemical characteristics. Endotheliocytes of the BBB have an internal thickness of 370±170 nm  ADDIN EN.CITE  [169] (less than intestinal EC), and so may facilitate transcellular transport of nutrients to the brain (see below). The number of BBB endothelial mitochondria is higher than in peripheral capillaries ADDIN EN.CITE  [170], due to the energy needed for passage by the active transport (see below) of different compounds through the cell. The cerebral endothelium has a low content of pinocytic vesicles ADDIN EN.CITE  [171], probably to restrict the non-selective penetration of compounds into endotheliocytes by pinocytosis. At the same time, the EC wall has a number of specialized channels that are responsible for the regulation of necessary substance flows (see below). Another BBB endothelium feature of importance is high enzymatic and P-glycoprotein (P-gp) expression  ADDIN EN.CITE  [172] which is believed to prevent the entry of potentially harmful compounds into the brain by their transformation or removal, respectively. 
	Pericytes, small oval cells which cover about 1/5th of the outer surface of capillaries, are the third main BBB component ADDIN EN.CITE  [173]. Most pericytes are located at points of EC contact. They play 3 important roles: the modulation of vessel sections because of their high actin content , the regulation of division and differentiation of endotheliocytes that are particularly important for the formation of new blood vessels (angiogenesis) , and, finally, macrophage activity  ADDIN EN.CITE  [174] and antigen expression , which allow them to exert their protective function ADDIN EN.CITE  [175]. Pericytes are very tightly connected to endotheliocytes. Often, their membranes are invaginated into each other. Gap junctions, that allow various molecules and ions to pass directly into cells, are another type of such connections ADDIN EN.CITE  [174].
	Bulky, star-shaped astrocytes are a different kind of BBB cell. Their branched end-feet cover 99% of the surface of brain capillaries, but these cells do not perform a direct barrier function, and the free diffusion of different compounds from EC to the brain is possible ADDIN EN.CITE  [176, 177]. Their main role is the induction of BBB formation, particularly the endothelium phenotype and its dense arrangement ADDIN EN.CITE  [178]. 
3.3.	Types of molecular transport  
	To ensure efficient oxygen and nutrient supply to the brain as well as waste evacuation, the BBB employs different paracellular and transcellular mechanisms of molecular transport. In particular, the entry of compounds into the brain can occur by paracellular diffusion, passive diffusion, diffusion facilitated by active transport by membrane transporters and, finally, by several types of endocytosis. Owing to the presence of tight junctions between EC, paracellular diffusion is suitable only for polar and very small molecules, i.e. water, glycerine, and urea ADDIN EN.CITE  [179]. All other compounds must pass by the transcellular pathway. 
	Passive or free diffusion is the simplest form of transcellular transport. It tends to establish a concentration or chemical potential equilibrium of substances, is nonsaturable, and requires no energy ADDIN EN.CITE  [180]. On the other hand, this type of diffusion is usually restricted to substances with higher lipophilicity and small size. Nevertheless, some works disclosed the possibility of passive diffusion, even for relatively large molecules. For example, Abbruscato et al. demonstrated that the passage of an 3H-labeled penicillamine-containing octapeptide (CTAP) into the CNS was not inhibited by the addition of unlabeled CTAP ADDIN EN.CITE  [181]. These findings concur with those of Banks et al. ADDIN EN.CITE  [182], showing that some octapeptide analogs of somatostatin also can cross the murine BBB by diffusion. 
	Facilitated diffusion or transport by selective membrane channels at the BBB involves the use of specialized membrane proteins which allow some compounds to cross the cells in both directions without energy expenditure, according to their concentration gradient. These transport membrane proteins can act as uniports (1 molecule in 1 direction), as symports (2 or more molecules in the same direction) or as antiports (2 or more molecules in opposite directions) ADDIN EN.CITE  [183]. However, flux is saturated by increasing concentrations and can be inhibited by competitive substrates. For example, to ensure the passage of significant quantities of water through endotheliocytes of the BBB that simple paracellular diffusion is unable to provide, hydrophilic channels are formed by aquaporin-4 (AQP4)  ADDIN EN.CITE  [184]and aquaporin-9 (AQP9) ADDIN EN.CITE  [185]. The role of AQP9 is also to form aquaglyceroporins necessary for glycerine, urea and methanoate ion transport ADDIN EN.CITE  [186]. The other important selective channels designed for glucose and vitamin C in their oxidated form are glucose transporters 1 (GLUT-1) ADDIN EN.CITE  [187]. Membrane peptides of the MCT (monocarboxylate transporter) and SLC (solute carrier) families ensure the passage of lactic, pyruvic, mevalonic, butiyric and acetic acids (MCT-1 and MCT-2), thyroid hormones (SLC16a2 and SLCO1c1), sulphate ions (SLC13a4), L-ascorbic acid and vitamin C (SLC23a2), amino acids (SLC 38a3), folate or vitamin B9 (SLC19a1), the cationic amino acids arginine, lysine, ornithine (SLC7) ADDIN EN.CITE  [188], respectively, and others ADDIN EN.CITE  [189]. Facilitated diffusion is also used during biphalin absorption ADDIN EN.CITE  [190]. 
	The mechanism of BBB transcellular penetration described above does not require any energy contribution on the part of the cells, but there are substances that must be transported against the electrochemical gradient. This requires not only special channels but also some ATP energy to drive these molecular "pumps" (active transport). For example, in the BBB, such transport is provided by influx transporters of enkephalin ADDIN EN.CITE  [191], vasopressin ADDIN EN.CITE  [192], [D-penicillamine2,5] enkephalin ADDIN EN.CITE  [193], and many efflux pumps produced respectively by the following gene families, ABC (MRP1-5 and BCRP pumps ADDIN EN.CITE  [194]), SLC (OAT3, OATP-A, OATP3A1, EAAT-1 ADDIN EN.CITE  [160]), and TAUT ADDIN EN.CITE  [189]. The role of these transporters is the elimination of foreign compounds, including many drug molecules ADDIN EN.CITE  [195]. The EC and astrocytes of the BBB contain a very high quantity of efflux P-gp, especially to increase their protective potential ADDIN EN.CITE  [196]. Some active transporters may be stereoselective, i.e. ASCT2 removing L-aspartic acid ADDIN EN.CITE  [197], while others do not present any substrate specificity ADDIN EN.CITE  [180]. 
	In addition to previously-mentioned mechanisms, endocytosis and transcytosis are an important way to pass through the BBB, especially for comparatively large particles, macromolecules or even their aggregates. In this case, the plasma membrane is invaginated around the object to incorporate it and form an internalized vesicle, which crosses the cell to be opened on the opposite side by a reverse mechanism, and release its contents. The BBB allows 3 types of endocytosis/transcytosis: pinocytosis, receptor- and absorptive-mediated endocytosis/transcytosis. 
	Pinocytosis or bulk-phase endocytosis, the non-saturable, nonspecific uptake of extracellular fluids which occurs readily and to a large extent in other cells of the body, takes place to a very limited degree in endothelial tissue of the brain microvasculature ADDIN EN.CITE  [198]. Thus, the other 2 endocytosis mechanisms are more frequent. In particular, receptor-mediated endocytosis/transcytosis, a highly-specific, energy-dependent transport pathway, needs a specific ligand at the particle surface to trigger the formation of vesicles ADDIN EN.CITE  [199].  For example, the TFR1 membrane receptor (or transferring receptor 1) is selective for transferrin ADDIN EN.CITE  [200], the INSR receptor and some other peptide hormones (cytokines) for insulin ADDIN EN.CITE  [159, 201], LEPR for leptin ADDIN EN.CITE  [202], IGF1R for the insulin-like growth factors IGF-I and IGF-II ADDIN EN.CITE  [203], etc.
	Absorptive-mediated endocytosis/transcytosis or cationic transport is the uptake of positively-charged particles launched by electrostatic interaction with the negatively-charged plasma membrane surface ADDIN EN.CITE  [204]. This type of transport across the BBB is faster than receptor-mediated endocytosis/transcytosis and allows more flow. Moreover, owing to its nonspecific and nonsaturable nature, cationic transport has been in focus for the development of many novel drug delivery systems ADDIN EN.CITE  [205].
3.4.	Passive anticancer drug targeting across the BBB
	As indicated previously, the BBB should be considered not only as a mechanical filter but also as a very specific biochemical barrier which engages particular mechanisms of protection and transportation. For example, the fact that passage across the BBB is normally easier for small molecules than for large ones  ADDIN EN.CITE  [206] cannot explain the penetration of very large particles, such as antibodies, proteins, RNA ADDIN EN.CITE  [207], and even some viruses  ADDIN EN.CITE  [208] and microorganisms ADDIN EN.CITE  [209], in the CNS. Thus, all factors should be taken into account to define BBB selectivity. However, it is still very problematic, and up to now 98% of drug molecules are not able to pass from blood to the brain ADDIN EN.CITE  [210]. Actually, one of the major challenges in pharmaceutical sciences is efficient drug delivery for the treatment of brain tumours. The prognosis and survival of most patients with these diseases are quite poor. For example, median survival for a patient with glioblastoma multiform is approximately 12-14 months, and has not improved substantially over the past 30 years ADDIN EN.CITE  [211]. It has been determined that the clinical failure of many potentially effective anticancer therapeutics is usually not due to the lack of drug potency, but rather to the inability to cross the BBB ADDIN EN.CITE  [212]. Thereby, it is obvious that new treatment modalities must be developed for the efficient delivery of anticancer drugs to the brain. In addition, therapeutic strategies without alteration of BBB properties, by administration in a more patient-compliant and safe manner (i.e. oral or i.v. forms), seem to be preferable. In this context, drug nano-encapsulation techniques (without chemical coupling between the vector and biologically-active unit), allowing passive BBB crossing (without any highly-specific interactions between NC and the capillary cell wall), represent interesting ways of improving CNS anticancer drug bioavailability. In particular, the main desirable functions of such NC are the capacity to pass the brain capillary wall, hiding encapsulated drug molecules from metabolic enzymes and efflux transporters, and, finally, to increase specificity towards tumour regions of the brain. Nowadays, there are different kinds of known drug NC for passive BBB penetration, namely, micelles, liposomes, polymeric NP, nanogels, and dendrimers.  
3.4.1.	Micelles
	Polymeric micelles, formed by self-assembly of large amphiphilic molecules in aqueous media, have not been tested for the delivery of chemotherapeutics to the brain in clinical practice. However, some investigations have demonstrated great potential of these nanostructures. For example, PluronicTM unimers (block copolymers based on ethylene oxide and propylene oxide) allowed the penetration of bovine brain microvessel EC monolayers by such active compounds as digoxin  ADDIN EN.CITE  [213] and DOX ADDIN EN.CITE  [214], particularly by inhibition of the P-gp efflux system ADDIN EN.CITE  [215]. In vitro and in vivo toxicity studies demonstrated no apparent toxicological issues with carriers at the human dose equivalent.
3.4.2.	Liposomes 
	Liposomes, small vesicles consisting of uni- or multilamellar phospholipid bilayers surrounding aqueous compartments, are some of the most widespread drug NC proposed for brain targeting. Generally, liposomes contain antineoplastic agents, such as daunorubicin, carboplatin, etoposide ADDIN EN.CITE  [216, 217, 218], etc. For example, the commercial liposomal formulations Doxil®/Caelyx® (Sequus Pharmaceutical Co.) with DOX  ADDIN EN.CITE  [219] and DaunoXome® (Nexstar Pharmaceutical Co.) incorporating daunorubicin  ADDIN EN.CITE  [220] are actually in clinical use, including pediatric populations, showing some effectiveness in glioblastoma and metastatic (high-grade glioma and teratoid/rhabdoid tumour) treatments ADDIN EN.CITE  [216]. Liposomes of both these formulations are based on modified phospholipids, i.e. PEG derivatives in the case of Doxil®/Caelyx®. For example, Depocyt® (ScyePharma Inc.), liposomal cytarabine, is actually serving in the clinical treatment of malignant lymphomatous meningitis. These liposomes are presented by non-concentric vesicles, each with an internal, aqueous chamber containing encapsulated cytarabine solution surrounded by a bilayer lipid membrane containing cholesterol, triolein, dioleoylphosphatidylcholine, and dipalmitoylphosphatidylglycerol [221]. Many other similar anticancer liposomal formulations are in the preclinical or clinical phase ADDIN EN.CITE  [222]. For example, modified lipid nanoliposomes containing irinotecan (CPT-11) were recently demonstrated to prolong tissue retention of the drug and enhance its anti-tumour effects in an intracranial U87 glioma xenograft model ADDIN EN.CITE  [223]. However, this type of nanovector is generally unstable in plasma due to its interaction with high- and low-density lipoproteins that results in too rapid release of the encapsulated drug ADDIN EN.CITE  [222].
Polymeric NP 
	NP, prepared from polymers and having a matrix structure that releases drugs by diffusion and degradation, are generally very promising materials to encapsulate anticancer drugs ADDIN EN.CITE  [224]. Some of these polymeric nanosystems have also demonstrated improvement in terms of drug amounts delivered to the brain. For instance, DOX-loaded NP, obtained by anionic polymerisation from butylcyanoacrylate (Fig. (10) (a)) and dextran, after coating with polysorbate(PSB)-80, significantly increased survival times in rats with glioblastoma ADDIN EN.CITE  [225]. However, this family of materials (Fig. (10) (a)(b)), coated with PSB-80, displayed some toxic effects toward the BBB  ADDIN EN.CITE  [226, 227] as their PEG-coated analogues accumulated in healthy tissue ADDIN EN.CITE  [228]. More interesting results were obtained with PEGylated-poly(hexadecylcyanoacrylate) NP (PEG-PHDCA NPs) (Fig. (10) (c)). In particular, after i.v. administration in rats bearing well-established intracerebral gliosarcoma, these carriers accumulated preferentially in tumoural tissues rather than in peritumoural brain tissues or in the healthy contralateral hemisphere. In addition, PEG-PHDCA NP concentrated much more in the gliosarcoma than their non-PEGylated counterparts, and did not display any toxicity towards the BBB based on the sucrose permeability test ADDIN EN.CITE  [229]. Despite very encouraging preliminary testing, PEG-PHDCA NP loaded with DOX have presented negative preclinical results in the rat 9L gliosarcoma model, attributed to aggregation of the encapsulated, positively-charged drug (DOX) to negatively-charged plasma proteins ADDIN EN.CITE  [230]. Thus, the physicochemical nature of the drug also should be taken into account in the formulation process.  Moreover, the cell internalization and intracellular distribution of PEG-coated PHDCA NP in rat brain endothelial cells (RBEC) was investigated recently. These NP displayed different patterns of intracellular capture. Depending on their specific surface composition, PEG-PHDCA NP were 48% in the plasma membrane, 24% in the cytoplasm, 20% in vesicular compartments and 8% associated with fractions of the nucleus, cytoskeleton and caveolae, indicating that PEG-PHDCA NP uptake by RBEC is specific and presumably derived from endocytosis ADDIN EN.CITE  [231]. 

Fig. (10). Structures of polymers used in polymeric NP.
(a) poly(butylcyanoacrylate), (b) PHDCA polymers, and (c) PEG-PHDCA copolymer.

	Other interesting materials for NP confection were synthesized by covalent binding between the biodegradable copolymer PLGA and 5 short peptides similar to some synthetic opioid peptides. In particular, the authors used the peptides H2N–Gly-L-Phe-D-Thr-Gly-L-Phe-L-Leu–X–CONH2, where X is L-Ser–OH or L-Ser–O–β-D-glucose, L-Ser–O–β-D-galactose, L-Ser–O–β-D-xylose and L-Ser–O–β-D-lactose. These peptides bear some resemblance to the matrix metalloproteinase (MMP-2200) but the Tyr present in that proteinase was substituted with Phe in order to avoid a potential opioid effect. The ability of these NP to cross the BBB was assessed in vivo by the rat brain perfusion technique after i.v. administration. Fluorescence and confocal microscopy disclosed that the vectors crossed the BBB, whereas NP made from pure PLGA were unable to do so ADDIN EN.CITE  [232]. Similar results were obtained with PLGA conjugated with heptapeptide H2N-Gly-L-Phe-D-Thr-Gly-L-Phe-L-Leu-L-Ser(O-β-D-Glucose)-CONH2 loaded with loperamide ADDIN EN.CITE  [233]. 
3.4.3.	Solid lipid NP (SLN)	
	SLN, obtained by mixing solid lipids and some surfactants, are also a potential antitumoural drug delivery system for brain targeting ADDIN EN.CITE  [234]. In vivo (mice) accumulation of camptothecin and DOX was observed in the brain after both oral and i.v. administration ADDIN EN.CITE  [235, 236, 237]. Significant paclitaxel uptake by the CNS was also noted in a short-term in situ rat brain perfusion experiment with SLN formulated with the biocompatible emulsifying wax Brij®   ADDIN EN.CITE  [238].
3.4.4.	Nanogels  
	Recently, a new, promising family of carrier systems was proposed for drug delivery to the brain. These so-called “nanogel” systems are made from a network of cross-linked ionic poly(ethyleneimine (PEI) and non-ionic PEG chains. When a biologically-active macromolecule is coupled with the nanogel by electrostatic interaction, the PEI fragments have a tendency to collapse, which results in decreased particle volume and size. Because of steric stabilisation of the PEG chains, the collapsed nanogel forms stable dispersions with a mean particle size of 80 nm. The nanogel has been tested as a potential carrier for oligonucleotide (ODN) delivery to the brain employing polarized monolayers of bovine endothelial cells. After i.v. injection of ODN-loaded nanogel in mice, no adverse toxic effects were observed and increased brain and decreased liver/spleen accumulations were noted, compared to free ODN ADDIN EN.CITE  [239, 240].
3.4.5.	Dendrimers
	Dendrimers, highly-branched, symmetrical macromolecules, represent novel, very interesting drug encapsulation systems. These compounds possess properties considerably different from linear polymers, such as monodispersity, globular shape, high level of surface functionality, the presence of internal cavities, and so on. The open nature of the dendritic architecture has led several groups to investigate the possibility of encapsulating drug molecules within the branches of dendrimers (dendrons). In particular, very encouraging data on methotrexate (MTX) delivery in an in vitro model of the BBB for the treatment of gliomas were reported, with polyester-polyether (PEPE) dendrimers having the same butanetetracorboxylic core, PEG spacers, and different branching agents: 3,5-dihydroxybenzoic acid, gallic acid, and 2,2-bis(hydroxymethyl)butyric acid ADDIN EN.CITE  [241, 242, 243]. The efficient penetration of dendrimers across bEnd.3 culture (a BBB model) and internalization into U87 MG and U343 MG-A tumour cells and their spheroids as paradigms of solid tumour tissue have been observed.  The antitumoural effect of MTX-loaded dendrimers was better than the result obtained with free MTX ADDIN EN.CITE  [242]. Moreover, these dendrimers did not manifest significant cytotoxic effects evaluated by MTT cell proliferation assay, erythrocyte lysis and bEnd.3 viability experiments, even at high concentrations ADDIN EN.CITE  [243, 244]. Study of BBB- crossing mechanisms showed relatively rapid transcytosis from 5 to 22 µg in the first hour. The increased number of PEG terminal chains and glucosamine grafting to the surface of dendrimers were found to augment permeability in this BBB model ADDIN EN.CITE  [242]. Transepithelial electric resistance measurements (​http:​/​​/​ca.wrs.yahoo.com​/​_ylt=A0geu8K5ZxxO_yAAZqLrFAx.;_ylu=X3oDMTE1cGVtcnBqBHNlYwNzcgRwb3MDMQRjb2xvA2FjMgR2dGlkA01TWUNBMDJfNzQ-​/​SIG=13p1lr15v​/​EXP=1310513209​/​**http%3a​/​www.pharmaceutical-int.com​/​article​/​trans-epithelial-electric-resistance-teer-measurements.html​) revealed that PEPE dendrimers did not cause significant tight junction disruption during permeation. Basal to apical efflux of dendrimers from the endothelium was very low (1-12%). A permeation investigation in the presence of the endocytosis inhibitor sodium fluoride (NaF) revealed inhibition of transport. In addition, the combination of NaF and low temperature (4oC) at the same time indicated that energy-dependent endocytosis was involved in the process ADDIN EN.CITE  [243]. Thus, the proposed PEG-containing PEPE dendrimers present a very interesting object for further study.  
	In conclusion, it should be noted that all approaches to reach passive nanoscale targeting across the BBB are able to more or less enhance the uptake of small and/or large active molecules into various tissues, but they usually lack selective/specific homing devices needed to target the brain and to selectively/specifically increase drug delivery to the CNS ADDIN EN.CITE  [245].
  
4.	THE GIT
4.1.	Structure and physiology of the GIT
The majority of drugs on the market are formulated for the oral route, most of them aimed at the blood circulation for systemic action. It is the most convenient and safe administration route, particularly for chronic delivery, but it poses a number of challenges for the formulator in terms of bioavailability (fraction of drug actually reaching the circulation) due to degradation by enzymes and harsh pH conditions, low solubility of some drugs or limited absorption by the GIT epithelium. The GIT is approximately 6 meters long with varying diameters. It consists of the esophagus, stomach, small intestine (the major digestive organ) and large intestine or colon. The luminal surface is not smooth, with deep, circular folds about 1 cm high, villi, mucosal projections about 1 mm long, and microvilli (plasma membrane microprojections), increasing the surface area of absorption to about 200 m2. Orally-administered drug molecules must stay for enough time in the intestinal lumen to be efficiently absorbed by intestinal cells via different mechanisms detailed below ADDIN EN.CITE  [246, 247, 248].
The GIT wall (at the small intestine level) is comprised of 4 main histological layers . The first layer, the “serosa”, is the outer layer of epithelial and supporting connective tissues. The second layer, the “muscularis externa”, contains 2 layers of smooth muscle, a thinner outer layer, with longitudinally-oriented muscle fibres and a thicker inner layer, with fibres oriented in a circular pattern. The “submucosa” is a connective tissue layer that consists of some secretory tissues richly supplied with blood and lymphatic vessels, including the lacteal, a wide lymph capillary at the center of the villi . The fourth layer, the mucosa, is composed of 3 layers: the “muscularis mucosa”, the “mucosa”, connective tissue, and epithelium. The intestinal epithelium acts as a physical and physiological barrier to drug absorption. It mainly consists of absorptive enterocytes and mucus-producing Goblet cells, endocrine and Paneth cells spread along the epithelium. The GIT epithelium is covered by a layer of mucus. Immuno-competent cells, such as B and T lymphocytes and dendritic cells are located beneath the epithelium. The small intestine wall possesses a rich blood network, and the GIT blood circulation is nearly a third of cardiac output flow, underlining the importance of exchanges between the GIT lumen and the blood circulation. The lymphatic system plays an important part in fat absorption from the GIT. The areas of lymphoid tissue close to the epithelial surface are called Peyer’s patches or the follicle-associated epithelium (FAE) and serve as immune sampling ports in the intestine. The FAE, separating organized, mucosa-associated tissues from the lumen, is composed of enterocytes and M-cells. Microfold “M-cells” are important in local immune responses to pathogens  ADDIN EN.CITE  [249] and could be harnessed to deliver macromolecules and oral vaccines ADDIN EN.CITE  [250]. M-cells have a disorganized brush border at the apical membrane with reduced microvilli and thinner surface mucus. Moreover, M-cells have specific surface-adhesion molecules that might be important features for active targeting ADDIN EN.CITE  [249]. 

Fig. (11). Structure GIT barrier: drug and NC transportation pathways. On the left, enterocytes, on the right M cell. A mucus layer is found on the apical side of enterocytes and M cell. (1) Paracellular route, (2) Transcellular route, (3) M-cell phagocytosis

4.2.	Routes of and barriers to drug absorption
Drug molecules encounter many barriers in the GIT once released from their dosage forms after they have dissolved in GI fluids. Drug molecules must be in solution and not bound to food or other materials within the GIT, chemically stable to withstand the GIT pH, and resistant to enzymatic degradation in the lumen. Finally, drug molecules need to diffuse across the mucus (“unstirred water layer”) and across the GlT membrane, the main cellular barrier in order to reach blood circulation ADDIN EN.CITE  [248]. The main drug absorption pathways from the GIT include carrier-mediated transcellular transport, vesicular transport, passive paracellular transport, passive transcellular transport through enterocytes and lymphatic uptake by M-cells.
4.2.1.	GIT environment
The GIT environment is characterized by peristalsis, variable pH, the presence of surfactants (bile salts), enzymes, bacteria, food and different types of secretions. GIT pH affects the dissolution rate and absorption of drug molecules. The GIT has a wide range of pH values in the stomach (pH 2-3), small intestine (pH 5-6) and colon (pH7). Moreover, pH depends of some variables, such as time, meal volume and content, and volume of secretions. In addition, the presence of enzymes in the GIT could have an effect on drug molecules that might be degraded, even before being absorbed. To provide effective treatment, the delivery system should offer good protection against these enzymes ADDIN EN.CITE  [247, 251].
4.2.2.	Mucus layer (“unstirred water layer”)
Mucus is a viscoelastic, translucent, aqueous, protective gel that is secreted throughout the GIT and different mucosal surfaces (pulmonary, nasal, etc.). Its thickness varies from 50 to 150 µm in the stomach to 15-150 µm in the intestine. It has a large water component (~95%), and its primary constituents, which are responsible for its physical and functional properties, are largely glycoproteins called mucins. Mucus acts as a protective layer and a mechanical barrier. It is a constantly changing mix of many secretions, proteoglycans and exfoliated epithelial cells. It is continually replaced from beneath as it is being removed from the GIT surface through acidic, enzymatic breakdown and abrasion (peristaltic movement of food towards the colon). Mucus is a strong barrier that could catch and immobilize NP before they have access to epithelial surfaces. GIT mucus is comprised of 2 layers, a firmly-adherent layer, slowly cleared of an “unstirred layer” close to the epithelium surface, and a luminal mucus layer, a “stirred layer”, a more rapidly-cleared layer ADDIN EN.CITE  [252]. It is secreted continuously and digested, so for drugs to be delivered to mucosal surfaces, they need to diffuse through the unstirred mucus layers adhering to cells ADDIN EN.CITE  [252, 253]. 
In addition to the mucus layer, not unlike the glycocalyx in blood vessels, a glycocalyx composed of glycoconjugate protein (that can be used for recognition), is present on cell surfaces, on microvilli in the small intestine. It could also provide adsorption sites on the surface ADDIN EN.CITE  [247, 254]. 
4.2.3.	Tight junctions and the paracellular route
The apical compartment of the lateral membrane consists of 3 components: tight junctions, adherent junctions and desmosomes (Fig. (11)). For desmosomes and adherent junctions, adjacent cell membranes are 15-20 nm apart, but are in contact at tight junctions, with the intercellular spaces being completely absent. Tight junctions act as gatekeepers of the paracellular route, regulating drug molecule flux and preventing the free movement of molecules in the paracellular space. Understanding the barrier function of tight junctions is necessary for developing absorption enhancers to deliver drugs via the paracellular route. Tight junctions separate the cell surface into apical and basolateral membranes. 
Diffusion is regulated by concentration differences and by electrical and hydrostatic pressure gradients between 2 sides of the epithelium. Tight junctions are the main barriers to this type of absorption ADDIN EN.CITE  [255, 256, 257].
4.2.4.	Transcellular route and P-gp efflux
The transcellular route comprises passive and active transport. For carrier-mediated transcellular transport, drugs are moved across membranes by protein transporters present on the apical membrane of enterocytes (generally energy-dependent).  The vesicular transport route consists of fluid-phase endocytosis and receptor-mediated endocytosis (caveolae-dependent, clathrin-dependent, caveolae-clathrin-independent, etc.) already detailed in Section 2.2. Vesicular transport could lead to the degradative pathaway (via lysosomes) or to exocytosis, transport across the epithelium (transcytosis) to the basolateral side of enterocytes near capillaries. For passive transcellular transport, drugs should be able to diffuse across the apical membrane, cytoplasm and basal membrane. The surface area available for passive transcellular transport makes up 99.9% versus 0.01% for the passive paracellular pathway.
P-gp is a membrane-bound transporter which excludes relatively lipophilic substrates from cell cytosol by active transport. It belongs to the super-family of ATP-binding cassette transporters expressed in cancer cells and responsible for chemotherapy resistance. P-gp is expressed in many normal tissues, such as the intestine, and is localized in the enterocytes, limiting absorption of drugs from the intestine by pumping them back to the lumen. NC have the ability to inhibit the effect of P-gp by limiting the presence of free drugs in cell cytosol (drugs confined inside NC) and/or by including P-gp inhibitors, such as PEG, on their surface. The mechanism of PEG P-gp inhibition is unknown, although direct interactions of the PEG chain inside the channel as well as phospholipid membrane action have been proposed ADDIN EN.CITE  [258, 259, 260]. 
4.2.5.	M-cells
Finally, transportation by Peyer’s patches, which contain M-cells found in the FAE at the base of villi, is important in the phagocytosis and endocytosis of NP and microparticles ADDIN EN.CITE  [249]. The physiological role of M-cells is to sample antigens present in the lumen to transport them to immune cells on their basal side, participating in protection against pathogens. They have high transcytosis activity, but represent less than 1% of the intestinal mucosa surface (but more in rodents). Particles could be taken up by M-cells via a specific (active endocytosis) or nonspecific (adsorptive endocytosis) mechanism ADDIN EN.CITE  [246].
4.2.6.	Pre-systemic metabolism
Drug molecules have to be stable to cross the GIT epithelium and to resist degradation and metabolism during passage. Drug molecules, which are absorbed from the GIT, are presented to the liver through the hepatic portal system before reaching the systemic circulation. While some metabolizing enzymes in the gut wall degrade drugs before they reach the systemic circulation, drug metabolism in the liver is very extensive. Drugs may be completely absorbed but incompletely available to the systemic circulation because of first-pass or pre-systemic metabolism by the gut wall and/or liver ADDIN EN.CITE  [261]. NC may mitigate these deleterious effects and increase bioavailability by protecting drug molecules from enzymatic degradation during intestinal passage and in the blood circulation ADDIN EN.CITE  [262].
4.3.	NC translocation and drug bioavailability
As a consequence of GIT morphology and physiology, drugs must overcome 3 barriers to be adsorbed efficaciously: conditions prevailing in the GIT lumen favouring degradation, the barrier mucus layer and, finally, transport across the epithelium itself toward the blood or lymphatic circulation. The same applies to drug-loaded NC. Depending on the encapsulation objective, NC could be either confined to the GIT or they could participate in drug delivery beyond drug translocation across the GIT intestinal mucosa. 
Their role could be limited, to protect against degradation and/or enhance drug solubilisation. In this scenario, intact NC are confined to the GIT lumen, but contribute to increased bioavailability by releasing drugs near the epithelium, acting as permeability enhancers, favouring adhesion and penetration of the mucus layer, and/or contributing to the opening of tight junctions.
On the other hand, drug encapsulation could involve NC translocation ADDIN EN.CITE  [263], along with the drug load, across the epithelium. It could even involve a role for the orally administered NC in drug distribution in the systemic circulation. Indeed, intact NC introduced in the blood circulation could provide the advantages of protection from metabolism, long circulation (if peggylated), targeting and improved PK, as discussed for i.v. administrated drug-loaded NC (see Section 2-1). While most studies have focused on blood drug levels or pharmacodynamic effects, few have followed the fate of NC ADDIN EN.CITE  [264]. However, in animal experiments, several types of NC, administered by the oral route, have been found in blood or organs ADDIN EN.CITE  [265], but, in general, they are poorly uptaken, the order of magnitude being a few % of the initial dose. There are also stability issues, as polymeric NC (polymeric NP, capsules) are more likely to be discerned in blood compared to liposomes or micelles that are most likely to undergo dissociation and degradation in the GIT lumen or during translocation across the epithelium.  Designing this type of NC is an engineering challenge and there is a limited set of data regarding NC translocated across epithelium to be discharged in blood circulation. The 2 type of NC (role limited to GIT lumen or aimed at blood circulation) may require different properties and they will be discussed below. 
4.4.	Optimizing NC physiochemical properties for oral delivery
4.4.1.	Increased drug absorption, drug dissolution and protection from degradation
NC could address the challenges identified above, by offering protection to drug molecules, and could also decrease the amount of drug needed for therapeutic action, thus reducing drug side-effects. This could be particularly significant for peptide and protein delivery, with insulin, for instance. Unprotected drugs, when introduced into the GIT, might not achieve the expected pharmacological effect because of many factors, such as drug stability in GIT fluid, incomplete absorption and permeability. Particles in the nano-scale range could improve bioavailability by increasing drug absorption by augmenting the dissolution rate ADDIN EN.CITE  [266], due to favourable surface/volume ratios and favourable physical drug states (crystallinity, amorphous or dispersed molecularly) in NC for release dissolution ADDIN EN.CITE  [246, 251, 267, 268]. Drug-loading efficacy varies with NC type and physicochemical properties of the compound to be encapsulated. It should be considered in regard to therapeutic dose to be achieved in blood. Lastly, NC stability is variable, and some are more sensitive than others (micelles, liposomes) to the GIT environment (acidity, bile salts, lipases, etc.).
4.4.2.	Mucus adhesion and penetrating properties
Mucoadhesion of NC
Increasing the residence time of drug-loaded NC in the small intestine might result in greater absorption of the drug or/and of the carrier itself. Adhesion to mucus has been proposed to extend NC residence time. For instance, mucoadhesion has been documented for NC surface modification with chitosan, the cationic charges of the polymer interacting with negatively-charged mucus ADDIN EN.CITE  [269]. The creation of disulfide bonds on mucus glycoprotein, with surface NC derived from thiols, has been proposed as a mucoadhesion strategy ADDIN EN.CITE  [270]. Broomberg et al. studied mucoadhesive anionic micelles, composed of the copolymer Pluronic-(poly (acrylic acid)), for oral delivery ADDIN EN.CITE  [271]. The mucoadhesive properties of the copolymer were linked to ionic interactions between mucins and carboxyl groups on the polymer, and the entanglement of Pluronic (PPG-PEG-PPG block) with the mucin network. Mucoadhesion is size-dependent, with maximum adhesion around 100 nm ADDIN EN.CITE  [272]. Examination of the behaviour of NC with different surfaces, i.e. PLA-PEG NP (200 nm, zeta potential -24 mv), PS NP (200 nm, +1 mv), chitosan NP (30 nm, +17 mv), revealed the effects of mucus adhesion (via interactions of hydrophobic surfaces with hydrophobic domains of mucus glycoproteins) on NC uptake in vitro ADDIN EN.CITE  [273]. pH-responsive NP (250 nm) of chitosan and poly(glutamic acid) encapsulating modified insulin were prepared. It was found that the drug carrier was retained in the GIT, while modified insulin show an increase in absorption into the systemic circulation, a result consistent with the mucoadhesion properties of chitosan NC and indicative of a protective role of NC toward the active  ADDIN EN.CITE  [274]
Mucoadhesion increases residence time. On the other hand, NC bound to mucin fibres are subject to natural and continuous clearance of the mucus layer (stirred layer) with as a consequence a maximum residence of about 4-5 h ADDIN EN.CITE  [252]. Moreover, adhesion to mucus hinders NC movement toward enterocytes or M-cells surfaces, limiting their cellular uptake and transcytosis to subepithelial tissues, and course in capillaries or lymph vessels. Strategies involving mucoadhesion (at least in case of strong interactions) may be limited to NC aimed at releasing drugs in the GIT lumen, increasing drug concentration at the site of absorption (near the mucosa epithelium).
Mucus-penetrating NC
Penetration of mucus is limited by gel porosity (NC size should be below gel mesh size to diffuse) and interactions between NC surfaces and gel components. Conflicting data on charges required to avoid ionic interactions with mucus resulted in an attempt to develop neutral hydrophilic surface modifications ADDIN EN.CITE  [252].
PEG, a hydrophilic polymer described in Section 2, has been used to coat NP. The result of coating is a decrease in zeta potential and improved NC stability. PEG prevents opsonisation by proteins present in the GIT and charge interactions. PEG (2 kD) minimizes interactions with anionic-charged hydrogel, allowing faster transport ADDIN EN.CITE  [275]. Pegylated 100 nm particles show slower transport and diffusion than 200 or 500 nm particles through the mucus layer. This could be explained by the existence of large pores in gel, allowing large NP to be transported, while smaller ones enter the more densely-packed gel (a process similar to size exclusion chromatography). It could also be explained by differences in the PEG layer structure in smaller NC, with a higher radius of curvature, permitting direct interactions between the NC surface and mucus ADDIN EN.CITE  [158]. Indeed, lowering PEG coverage to 40% and increasing PEG length to 10 kD, decreases NC diffusion in the mucus layer ADDIN EN.CITE  [252]. PEG’s effect on further translocation across the epithelium by different pathways remains to be clarified ADDIN EN.CITE  [265, 273, 276].
4.4.3.	Translocation across tight junctions
In normal physiological conditions, translocation of NC through tight junctions is severely limited by their relatively small surface area and tightness. In fact, NC passage is dependent on junction opening. NC made of chitosan or with chitosan on the surface (and also co-administration of free chitosan) have displayed the ability to transiently open tight junctions between epithelial cells, facilitating the transport of drug molecules ADDIN EN.CITE  [255, 257]. Other permeability enhancers have been proposed ADDIN EN.CITE  [277], but all of them have intrinsic toxicity and indiscriminately open the junctions to all kinds of GIT contents ADDIN EN.CITE  [256]. 
4.4.4.	Translocation across enterocytes
NC translocation across enterocytes can occur by transcytosis ADDIN EN.CITE  [265], consisting of 3 steps, i.e. uptake of the NC at the apical side, intracellular trafficking toward the basolateral side and exocytosis. The different endocytosis routes have been described in Section 2.2 for EC and are similar in enterocytes. Size and surface properties are the main determinants of transport efficacy and pathway chosen by NC.
Particle size, a critical characteristic of NC, has a direct effect on cellular uptake. It has been well-accepted in research that small-size particles could be taken up by enterocytes and M-cells, enterocytes having a maximum uptake of 50-100 nm particles, while M-cells can engulf particles up to the micrometer range ADDIN EN.CITE  [249, 265, 278]. Peyer’s patches have up to 200-fold higher uptake of PLGA NC than non-patch tissues. 100-nm NC diffuse in the submucosal layers while larger size particles (micrometer range) are predominantly localized in the epithelial lining of tissues ADDIN EN.CITE  [267, 279]. Size, being a key parameter, PS NP uptake increases with a decrease in particle diameter. Moreover, Peyer's patch uptake predominates over enterocytes uptake, even if the former represents only about 1% of the intestinal mucosal surface ADDIN EN.CITE  [265].
The presence of hydrophilic polymers on the surface of NP might increase transport through mucosal surfaces ADDIN EN.CITE  [280, 281], although conflicting results have been reported. The adsorption of hydrophilic block-co-polymers (poloxamer) onto polystyrene NC markedly reduces uptake in the small intestine ADDIN EN.CITE  [265]. For instance, 300-nm PLGA particles were found to migrate from the GIT into different tissues and organs, especially the liver ADDIN EN.CITE  [282]. When modified on the surface with PEG and chitosan, they migrated from the GIT into peritoneal macrophages ADDIN EN.CITE  [283]. These results are consistent with the importance of polymeric NC stability as well as surface modification to cross the GIT epithelium. Endocytosis pathway depends on surface properties. PLGA particles, or chitosan NC, for instances, are predominantly endocytosed via clathrin-dependent pathways ADDIN EN.CITE  [264]. In contrast, it has been demonstrated that the bioavailability of paclitaxel loaded in lipid nanocapsules (from 25 to 135 nm) is improved across CaCo-2 cell monolayers because of this type of NC capacity to improve transport, predominantly via caveolae-dependent pathways ADDIN EN.CITE  [284, 285].
Nonspecific adhesion properties might improve NC localization and transport. Lectins are saccharide-binding membrane glycoproteins, which can bind reversibly to sugars either in free form or supported on other membranes. They might adhere to the GIT surface to improve absorption and permeability. Lectin binding was found to be favoured at neutral pH and reduced at acidic pH. Tomato lectin has been reported to increase bioadhesion and conjugate with mucus gel. Surface modification with covalent attachment of tomato lectin molecules indicated widespread uptake of PS NP by enterocytes rather than by Peyer’s patches ADDIN EN.CITE  [265]. Wheat-germ agglutinin, a type of lectin conjugated with PLGA NP, showed improved intestinal absorption of thymopentin as a result of lectin’s bio-adhesive effect. Lectin conjugation with the NP surface ameliorated NP transport across the intestinal mucosa by increasing interaction with mucus or epithelial cells ADDIN EN.CITE  [286, 287]. Gliadin, another mucoadhesive agent, was conjugated with NP carrying amoxicillin. These NP were more effective for local treatment of H. pylori than conventional GIT therapy ADDIN EN.CITE  [288].
4.4.5.	Translocation across M-cells
The ability of M-cells to transport different materials by transcytosis (either phagocytosis or endocytosis) has made them a good target to deliver vaccines and drugs ADDIN EN.CITE  [289]. Moreover, steric hindrance by mucus layer is lowered as the layer over M-cells is thinner than over enterocytes. Bioadhesive materials, which prolong the residence time of drugs or vaccines and increase uptake by binding to intestinal mucus or the apical surface, have served to improve NC delivery efficiency.  M-cells in the intestine might be targeted for mucosal vaccination to transport antigen to induce mucosal immunity. PEGylated PLGA NP were also designed to target M-cells for oral vaccination ADDIN EN.CITE  [250]. Naked PLA particles (in the 200 nm range), followed by fluorescence, showed initial accumulation in mucus and then moved to M-cells (in 15 min). Further examination disclosed NP in immune cells in subepithelial tissue, confirming barrier crossing ADDIN EN.CITE  [290]. In summary, optimal NC size seems to be below 1 µm with maximal uptake between 100 and 200 nm. NC with an hydrophobic surface are transported more than NC with a hydrophilic surface, and hydrophobic surface NC are transported more than charged surface NC ADDIN EN.CITE  [277].
4.5.	NC as effective oral drug carriers
The following examples have been selected to illustrate the challenge of delivery with different types of NC and do not represent an exhaustive compilation of studies produced in this field.
Polymeric NP
Polymeric NC are among the most promising strategies to improve oral delivery, because of their stability in the GIT, protection of encapsulated actives and the ease with which their physicochemical and drug release characteristics can be modulated ADDIN EN.CITE  [277]. A large variety of materials could be exploited to prepare NP (matrix-structure nanospheres or capsules) and to modify their surfaces.  Synthetic (polyesters, acrylates, etc.) and natural materials, such as chitosan, dextran, gelatin, etc., are being incorporated to prepare these NC. Polymeric NP have several advantages for GIT delivery over other NC, especially because they are more stable. Polymeric NP are distributed more uniformally in the GIT; therefore, the drug is absorbed more uniformally and the risk of local irritation is reduced (compared to unique dosage forms). Insulin has been the focus of research for formulation in effective NC for oral delivery. Increasing the hydrophilicity of chitosan-triphosphate NP containing insulin leads to a prolonged hypoglycemic effect attributed to the mucoadhesive and protective action of NP ADDIN EN.CITE  [291]. Similarly, poly(isobutylcyanoacrylate) NC encapsulating insulin manifest improved effects on glycemia in a rat model over oral free insulin ADDIN EN.CITE  [292]. It is noteworthy that the percentage of dose actually crossing the GIT mucosa is increased but stays low (a few % of bioavailability), requiring higher doses increasing potential toxic effects and underlining the limitations of these approaches ADDIN EN.CITE  [277].
Besides mucus penetration, PEG addition to the PLA NP surface has been reported to enhance particle stability in biological fluids, preventing protein and enzyme absorption and thus protecting from the degradation of NC and their load ADDIN EN.CITE  [293].
Liposomes and lipid-based NC
Liposomes can serve as efficient oral drug carriers to improve drug bioavailability because of their ability to pass through lipid bilayers and the cell membrane. Because of their structure, liposomes can be designed for water- and lipid-soluble drugs. Unfortunately, for oral drug delivery, they have limited applications because of their instability in the GIT environment ADDIN EN.CITE  [294]. Their role seems confined to increasing the bioavailability of low-solubility drugs. They appear to accumulate in mucus, prolonging their residence time but limiting their diffusion. They have been proposed as vaccination adjuvants and as antigen presentation to M-cells ADDIN EN.CITE  [295].
Lipids and phospholipids in the form of solid lipid particles (SLPs) are an interesting alternative to polymeric matrix NC for hydrophobic drug and protein encapsulation ADDIN EN.CITE  [294]. For instance, camptothecin-loaded SLPs coated with poloxamer 188 (200-nm particles with zeta potential around -70 mV) display increased bioavailability compared to the oral, soluble drug form ADDIN EN.CITE  [235]. Similarly, insulin encapsulated in lectin-modified SLPs presents increased bioavailability ADDIN EN.CITE  [296].
Micelles
Micelle polymers are composed of a hydrophilic shell (usually PEG) and a hydrophobic core. Micelles have been studied as drug delivery systems to improve solubility, absorption and protect drug molecules. Although polymeric micelles ADDIN EN.CITE  [297, ADDIN EN.CITE  298] have a longer lifespan than surfactant micelles, there are still some challenges facing their preparation, such as stability, improved drug loading, resistance to dilution in the GIT, and narrow size distribution ADDIN EN.CITE   ADDIN EN.CITE  [262, 264, 299, ADDIN EN.CITE   ADDIN EN.CITE 300]. Micelles have been mainly studied to improve the drug solubilisation of highly hydrophobic drugs, such as taxanes, for oral chemotherapy ADDIN EN.CITE  [301]. There are no clear indications that they can cross the musocal epithelium other than in the form of isolated copolymers ADDIN EN.CITE   ADDIN EN.CITE [298, 302].
Hydrogel NC
NC delivery systems, hydrogel nanospheres, fabricated from poly(methacrylic acid) (PMAA) and PEG, and loaded with the chemotherapeutic agent bleomycin, have disclosed an improved effect because of their mucoadhesive properties and P-gp inhibition ADDIN EN.CITE  [303]. Negatively-charged 700-nm NC of alginate and chitosan encapsulating insulin were prepared. The results indicate a decrease of glycemia of about 40% in diabetic rats. Encapsulation into mucoadhesive NC was a key factor in the improvement of oral absorption and activity ADDIN EN.CITE  [304]. 400-nm alginate and dextran sulphate NC encapsulating insulin augmented GIT uptake (13% bioavailability) and decreased glycemia in a rat model. This superior uptake seems to be linked to the uptake of NC by small intestine epithelial cells ADDIN EN.CITE  [305].
Dendrimers
Dendrimers have a distinctive small particle size and could serve as solubilizing agents for both hydrophilic and hydrophobic drugs. Poly(amido amine) (PAMAM) dendrimers have been reported to improve the intestinal absorption of poorly soluble drugs but appear less efficient with macromolecular drugs. Moreover, the dendrimer dose should be kept low to reduce toxicity ADDIN EN.CITE  [306]. In vitro, PAMAM toxicity was diminished by surface modification by lauroyl chloride, while their permeation through Caco-2 cell monolayers was increased. Both PAMAM and lauroyl dendrimers can cross epithelial cell monolayers via paracellular and transcellular pathways ADDIN EN.CITE  [307]. Drug solubilization in dendrimers occurs either by single drug molecule encapsulation or drug molecule attachment at the surface. PAMAM and poly(propyleneimine) dendrimers have been studied to enhance the solubility of some drugs for oral administration ADDIN EN.CITE  [308]. Dendrimers might be tested to improve drug permeability and bioavailability because their small size allows them to enter cells and to cross the intestinal epithelium ADDIN EN.CITE  [309].  
4.6.	Conclusion
Encouraging results with some NC and actives have been reported in the literature on oral delivery. However, low bioavailability (percentage of the initial dose) and lack of control of the absorbed dose (crucial, for instance, in the case of insulin) still hinder the development of drug-loaded NC for oral delivery. The physicochemical characteristics of NC need to be optimized to achieve the desired goal, particularly in the perspective to deliver intact and functional NC into blood circulation. The challenge is to integrate all the properties necessary to cross each barrier toward blood delivery, the properties sought for blood circulation and targeting (see section 2.1 and 2.2) in the same NC.

5.	PASSIVE PULMONARY TARGETING
In addition to being a fast pathway for drug administration, pulmonary drug delivery is an interesting and very promising approach to drug therapy as it avoids first-pass metabolism (in contrast with the oral route) and is non-invasive (as i.v. could be). Also, the lungs have the advantage of large surface contact over the alveoli, possessing a thin air-blood barrier and excellent pulmonary perfusion ADDIN EN.CITE  [261].
	NC for the pulmonary route provide a viable alternative to drugs intended for parenteral administration. Indeed, this delivery route transports drugs directly to the site of action (on the lung wall), thus reducing side-effects. Despite their many benefits, NC must overcome several obstacles when inhaled, such as mucociliary clearance, respiratory secretions (mucus and alveolar fluid), branching of the airways and macrophages uptake. To develop effective NC, it is important to understand the anatomical and physiological properties of the respiratory tract. In this section, we will first discuss lung anatomy and physiology, then the mechanisms of particle deposition, the possible pathways of particle internalisation, the impact of mucus on NC delivery, and finally physicochemical properties and some examples of NC currently under study.
5.1.	Lung structure and physiology
The airways are divided into 2 parts: the upper airway includes the nose, throat, pharynx and larynx, while the lower tract contains the trachea, bronchi and bronchioles, which are connected to channels leading to alveolar sacs and alveoli. The lungs are organs of respiration. The oxygen introduced into the lungs goes directly to the alveolar cells and diffuse through the thin barrier to reach alveolar capillaries. As for carbon dioxide it follows the reverse path ADDIN EN.CITE  [310]. The lungs contain about 2-6 x 108 cells, providing an area of approximately 100 m2 in humans. The alveolar surface area exposed is normally covered by a surface film of surfactant. Branching of the airways does not favor the inhalation of foreign particles and microorganisms ADDIN EN.CITE  [310, 311].
At the physiological level, epithelial cells of the alveoli are called pneumocytes. They cover the interior of the cells and contribute to their function. There are mainly 2 types of pneumocytes. Type I pneumocytes are responsible for gas exchange (passive diffusion and active oxygen and carbon dioxide). They are fragile and degrade rapidly on account of germs and pollutants; thus, they are difficult to repair. They are relatively thin (about 5 µm) and cover about 90% of the total alveolar surface. A single cell covers up to 400 m2 of the alveoli interior, but the total number of type I cells does not exceed the number of type II pneumocytes. Type I pneumocytes are closely coupled to capillaries from which they are separated by the basement membrane, allowing the diffusion of respiratory gases ADDIN EN.CITE  [261]. Type II pneumocytes (or granular pneumocytes, and large alveolar cells), in turn, have the distinction of being cube-shaped or rounded. Their cytoplasm is rich in organelles, a sign of active metabolism, confirming the presence of overdeveloped endoplasmic reticulum and Golgi apparatus. These cells are characterized by specific organelles, the lamellar bodies, secreting pulmonary surfactant. There are 6-7 type II cells per alveolus. Type II pneumocytes are believed to be essential for cellular repair after damage caused by viruses or chemical agents ADDIN EN.CITE  [312]. They divide, by losing their lamellar bodies, and flatten themselves to replace type I pneumocytes when they die.
Fig. (12). Structure of alveoli. Cross-section of an alveolus showing a capillary, alveolar macrophage, surfactant layer, type I and type II cells (adapted and modified from [313])

5.2.	Deposition mechanism of particles
Whether solid or liquid, nebulization and aerosol inhalation are 2 forms of pulmonary administration. Several factors, such as respiratory rate, lung volume and health status must be taken into account when designing a formulation intended for the pulmonary delivery. However, the size of inhaled particles is one of the most important elements in the development of forms intended for inhalation. Indeed, particles must have size distribution less than about 5 or 6 µm and less than 2 µm for deposition in the alveolar region. The 4 main mechanisms affecting deposition and the pathway of particles in the lungs are gravitational sedimentation, impaction, diffusion and interception ADDIN EN.CITE  [261]. They are developed below ADDIN EN.CITE  [312, 314]. 
5.2.1.	Gravitational sedimentation
Sedimentation corresponds to the gravitational pull of particles on the airway wall. When particles are moving in air, gravitational attraction and air resistance force their deposition on the lung surface, mainly in the bronchi and bronchioles. The gravitational settling of inhaled particles depends on their size, density and residence time in the respiratory pathway. Thus, particles with aerodynamic diameters less than 0.5 µm will not be affected by this settling. On the other hand, the probability of hygroscopic particles settling down by sedimentation increases as their size and mass grow with moisture in the lung airways.
5.2.2.	Impaction
Impaction is the projection of particles against the airway wall, usually occurring in the upper lungs. Thus, when confronted at the junction of 2 airways, many of them continue straight ahead and hit lung wall surfaces on their trajectory (sometimes adhering to the wall), rather than follow airflow. The probability of impaction depends on air velocity and particle mass. It is also closely linked to particle inertia. This mechanism of deposition is particularly important for particles with a diameter greater than 5 µm, and even more for those above 10 µm.
5.2.3.	Diffusion
This delivery mechanism, also known as Brownian motion, is a major problem involving the random motion of particles less than 0.5 µm in diameter from a region of high particle concentration to a lower one. The smaller the particle, the more significant is its agitation energy, and it randomly deposits on walls. Unlike the mechanism of impaction, diffusion occurs mainly in the lower lungs, i.e., in the bronchioles and alveolar region.
5.2.4.	Interception
Interception is when a particle comes into contact with a surface of the respiratory organs because of its size or shape. It is also related to electrostatic forces and arises when the distance between the particle and the wall is less than the size of the particle.
5.3.	Respiratory secretions as a barrier to NP deliverance
Mucus, i.e., respiratory secretion, is usually located in the upper airways. The alveolar area contains no mucus but rather alveolar fluid, maintaining surface tension in the alveoli. Respiratory mucus, mainly secreted by glandular cells, forms a viscoelastic and continuous layer on the respiratory epithelium surface, thus becoming a natural barrier that protects the lungs from hazardous particles that could enter during normal breathing through the nose. Mucus is involved in mucosal defense through its anti-infectious and protease inhibitors as well as its mechanical and rheological properties. However, the alveolar area does not contain such defense but can rely on macrophages to trap and eliminate foreign bodies that try to penetrate the alveoli ADDIN EN.CITE  [252, 275, 315]. Residues from this operation are pushed to the mucociliary escalator, then to the bronchioles for expulsion from the lungs. As GIT mucus, lung mucus is composed of 95 to 97% water containing proteins (1% of glycoproteins), lipids (1%) and ions. Glycoproteins, or mucins, are large molecules (0.5-40 000 KDa) with polypeptide chains that are able to connect hundreds of glycan chains. The mucin network can form pores, with diameters ranging from 20 nm to 800 nm. In general, upper airway lung mucus thickness is 15 m compared to 55 m in bronchi ADDIN EN.CITE  [252, 316].
Mucus characterization, whether in terms of its composition, structural organization, thickness, flow rate or time of disposal, is crucial in the development of NC ADDIN EN.CITE  [317]. Similarly, NC surface properties and size characterization are important factors to consider for barrier crossing. NC must be able to penetrate mucus faster than mucus renewal and mucus clearance to overcome the barrier. For example, particles with sizes larger than mucus pores will likely have difficulty diffusing. Particles with no affinity for mucus (i.e. adhesive forces, electrostatic interactions with carboxyl groups or sulphate on mucin, hydrophobic forces, interpenetration of polymer chain and hydrogen bonds) will have trouble adhering on it and will be quickly eliminated. Most experiments on mucus focused on GIT mucus. Studies conducted on lung mucus were distinctively limited to patients with cystic fibrosis. These patients suffer from over-excretion of pulmonary mucus, which facilitates sampling. To our knowledge, only a few groups have been interested in investigating the impact of mucus on pulmonary NC, and rarely did they focus on alveolar fluid. For more details on this subject, however, readers are encouraged to consult the following reviews ADDIN EN.CITE  [252, 310, 318]. Below is a non-exhaustive list of studies that were conducted.	
Wang et al. reported that NP as large as 500 nm in diameter rapidly diffuse through mucus to the extent that they are densely covered with low MW PEG ADDIN EN.CITE  [319]. They showed that polystyrene NP are trapped in mucus because of bonds formed between hydrophobic polystyrene beads and the hydrophobic domains in mucin fibers. They believe that coating particles with PEG creates a hydrophilic and neutral shell that minimizes hydrophobic adhesive interactions with mucus. Particles coated with 5-kD PEG retained quick mucus-penetrating properties, but particles coated with 10-kD PEG lost them, indicating that MW between 5 and 10 kD was critical, with transition of dense PEG coating from muco-inert to mucoadhesive. High MW PEG (≥10 kD) can be highly mucoadhesive due to the interpenetration of PEG fibers with mucus and hydrogen bonds between oxygen atoms in PEG and sugars on glycosylated mucins. Although this study was performed on cervico-vaginal mucus, the same conclusion can be drawn for mucous membranes of the respiratory pathway as they have similar rheological properties.
As already mentioned for GIT mucus, it is well-known that PEGylation enhances the transport of NP across the mucosal barrier and decreases clearance by alveolar macrophages. Lai et al. discerned that larger PEGylated polystyrene NP (500-nm diameter) can cross fresh, undiluted human mucus more efficiently than smaller ones (100-nm diameter) ADDIN EN.CITE  [252].
5.4.	Internalization pathways of inhaled NP to the blood circulation
Translocation mechanisms of NC have been the subject of much research over several years, often generating contradictory results. Patton et al. suggested that there are 2 different mechanisms of translocation from the lungs to the systemic circulation ADDIN EN.CITE  [320]. In general, paracellular transport occurs fast (between 5 and 90 min) for macromolecules with MW >40 kD and size >5-6 nm, and transport is much slower ("receptor-mediated transcytosis") when the particles have MW <40 kD and size <5-6 nm (see Fig. (13)). Although, studies are conflicting, researchers agree that 2 physicochemical parameters − size and surface charge − influence the translocation of particles to the systemic route.
5.4.1.	Size
By deploying 13C-labeled NP of 20-29 nm, Oberdörster et al. confirmed a rapid clearance/translocation of particle during inhalation exposure. After 18 and 24 h, authors noticed increased 13C hepatic levels, showing that a large amount of NP reached the blood circulation. However, authors do not explain this uptake by pulmonary epithelium crossing but rather by a significant particle absorption by the GIT due to mucociliary clearance as well as post exposure GI uptake of NP as the animals licked their contaminated fur ADDIN EN.CITE  [321].
Meiring et al. (2005) stipulated that NP could follow various cellular pathways of translocation, such as clathrin, pinocytosis and caveolae. They could have been the route for iridium NP (18 nm in size) in a model of isolated perfused rabbit lungs ADDIN EN.CITE  [322]. Heckel et al. showed that 7% of colloidal gold NP (4-nm size) were internalized by EC and lung epithelia in New Zealand white rabbits. Infusion of lipopolysaccharide (LPS) caused mild pulmonary edema, and transendothelial passage was multiplied by a factor of 5, while 14% of particles accumulated in the interstitium and 11% reached the alveoli ADDIN EN.CITE  [323].
Furuyama et al. (2009) administered gold colloid or fluorescein-labeled polystyrene NP (20 and 200 nm) ADDIN EN.CITE  [324]. Gold colloid particles were detected on the EC surface, on the alveolar surface, in endocytotic vesicles of alveolar epithelial cells, and in the lung basement membrane after 15-min of intratracheally instillation. A small but noteworthy amount of gold was detected in the extrapulmonary organs. After the administration of 20- or 200-nm fluorescent particles, free particles were noted infrequently in blood vessels, on the endocardial surface and in the kidneys and liver only in mice that received 20-nm particles, whereas phagocytes containing 20- or 200-nm particles were found in extrapulmonary tissues. Thus, small amounts of ultrafine particles were transported across the alveolar wall into the blood circulation via endocytotic pathways, but particle-laden alveolar macrophages translocated both ultrafine and fine particles from the lungs to the extrapulmonary organs ADDIN EN.CITE  [324].
In their study, Takenaka et al. exposed rats to 16-nm gold particles for 6 h ADDIN EN.CITE  [325]. After 7 days, they observed a high percentage of gold NP in lung tissue and a low quantity in blood. NP were also encountered in the vesicles of alveolar macrophages. They concluded that gold particles in alveolar macrophages are internalized by endocytotic pathways and the uptake of gold particles by alveolar macrophages is limited ADDIN EN.CITE  [325].
Chen et al. tested radiolabeled PS particles uncoated and coated with LPS with average diameters of 56.4 and 202 nm, respectively ADDIN EN.CITE  [326]. The results indicated that the pulmonary deposition of radioactivity was virtually similar for both sizes. Only small amounts of radioactivity (~2%) were recovered in blood shortly after the administration of both particle types in healthy rats. However, the extent of ultrafine size particle translocation into blood after pretreatment with LPS was significantly higher (~4%) in comparison to larger particles (~2%). These authors concluded that only a small fraction of intratracheally-instilled ultrafine particles can pass rapidly into the systemic circulation, but this translocation is markedly increased after LPS pretreatment. 
Yacobi et al. investigated the translocation mechanisms of fluorescently-labeled polystyrene NP (20 and 100 nm) through rat alveolar epithelial cell monolayers (RAECMs) ADDIN EN.CITE  [327]. These results of confocal laser scanning microscopy revealed no intracellular co-localization of NP with early endosome antigen-1, caveolin-1, clathrin heavy chain, cholera toxin B, or wheat germ agglutinin. They concluded that NP translocate primarily transcellularly across RAECMs, but not via known major endocytic pathways, with the contribution of the lipid bilayer of cell plasma membranes ADDIN EN.CITE  [327].
5.4.2.	Surface charge
In addition to studying the impact of particle size, some authors analyzed the impact of surface charge. In previously-described work, Yacobi et al. tracked NP translocation according to different surface charges. Fluorescently-labeled polystyrene NP were either negatively charged (with a carboxylate function) or positively charged (with an amidine function). Trafficking data revealed that the surface charge on NP was largely affected by transport rates, with positively-charged NP being 20-40 times more rapid than negatively-charged ones across the alveolar epithelium (RAECMs) ADDIN EN.CITE  [328].
Choi et al. (2010) studied fluorescent NP with varying chemical composition, shape, size and surface charge. They demonstrated that NP with hydrodynamic diameter (HD) less than ≈34 nm and a non-cationic surface charge translocate rapidly from the lungs to mediastinal lymph nodes. NP with HD <6 nm were able to traffic rapidly from the lungs to the lymph nodes and bloodstream, and then cleared by the kidneys ADDIN EN.CITE  [329]. Studies showed the presence of albumin and lecithin in alveolar epithelial fluid to be essential constituents to facilitate NC epithelial cell uptake. PS 240 nm NP have been shown to be translocated across the alveolo-capillary barrier when coated with lecithin while uncoated PS NP were not transported ADDIN EN.CITE  [330]. 

Fig. (13). Proposed NC transport pathways across alveolar and vascular endothelial cells. Possible translocation mechanisms across the 2 cell layers: (A) Alveolar epithelial tight junctions (paracellular transport), (B) Caveolar receptor-mediated transcytosis, (C) Caveolar trans-endothelial transport, (D) Trans-endothelial channel, (E) Vascular endothelial cell tight junction

5.5	Physicochemical characteristics of NC
Particle size is a critical factor that determines the location of particles deposited in the lungs ADDIN EN.CITE  [331]. It is expressed by aerodynamic diameter that takes size, density and particle shape into account. Large particles (HD >6 µm) have strong momentum and tend to settle in the upper regions of the respiratory path instead of following the course of breathing. The movement of small particles (HD <1 m) is governed by Brownian motion, and most of them will be exhaled during normal breathing. For effective deposition in the lower respiratory path, optimal particle size must have an aerodynamic diameter between 1 and 5 µm. On the other hand, for smaller size particles, the probability of deposition in the lower regions of the lungs will be increased (due to diffuse mobility). NP smaller than 100 nm seek refuge in the alveolar region with fractional deposition of about 50%. These fine particles enter the lungs agglomerated and can easily break into smaller particles during deposition (Fig. (14)) ADDIN EN.CITE  [332, 333].

Fig. (14). NC Predicted fractional deposition of inhaled particles in the human respiratory tract. (data reformatted from [332])

In addition to the complex anatomy and physiology of the lungs, air sacs are rich in macrophages that constitute a vital factor in immune defense. Particles between 1 and 5 µm are typical of bacteria size and are easily engulfed by phagocytosis; of course, this limits NP translocation in the bloodstream. To remedy the problem, Edwards et al. improved insulin absorption in the lungs by developing large porous particles (LPP) with geometric diameter (gd) of ~10 µu and density (ρ<0.1 g cm-3), facilitating deposition in the alveoli and decreasing the chances of phagocytosis ADDIN EN.CITE  [331].
5.6	Impact of key physicochemical properties on NC efficacy
5.6.1	Microparticles and NP 
Compared to liposomes, microspheres have more stable physicochemical behaviour in vivo and in vitro and should provide slower release and longer pharmacological activity of encapsulated drugs. Microspheres are less hygroscopic and are thus less liable to swell in the presence of moisture located in the lungs ADDIN EN.CITE  [334]. 
There have been significant improvements in aerosol particle technology in recent years [331]. Particles with mass density (ρ<0.4 g/ml) and increasing particle geometric size (10–20 µm) were inspired deep into the lungs and escaped alveolar macrophages until they delivered their drug. LPP, by virtue of their porosity, display an aerodynamic diameter much lower than GD, facilitating their deep lung deposition. Inhalation of large porous particles elevated systemic levels of both insulin and testosterone in comparison to small non-porous particles. Edwards et al. demonstrated that inhalation of large porous insulin particles resulted in elevated systemic levels of insulin and suppressed systemic glucose levels for 96 h, whereas small non-porous insulin particles had such an effect for only 4 h. High systemic bioavailability of testosterone was also achieved by inhalation delivery of porous particles with a mean diameter (20 µm) approximately 10 times that of conventional inhaled therapeutic particles. Large, porous PLGA particles (density (ρ)=0.4 g.cm-3, diameter 5 μm) appeared to be more efficient for the pulmonary drug delivery of inhaled particles than small porous or non-porous particles (ρ 1-0.5 g.cm-3, d=5 μm) ADDIN EN.CITE  [331, 335]. 
This efficacy was attributed to the fact that large particles aggregate less and disaggregate more easily under shear forces than smaller, non-porous particles – all other considerations being equal ADDIN EN.CITE  [336, 337]. Hence, they appear to aerosolize more efficiently from a given inhaler device than conventional therapeutic particles. Particle size is crucial in the appearance of inflammatory symptoms. Indeed, ultrafine polystyrene particles (60 nm) induced much more pro-inflammatory activities than NP with a size range between 200 and 500 nm. And it could be attributed to their much more pronounced specific area ADDIN EN.CITE  [338].
5.6.2	Liposomes
The utilization of liposomal drug formulations for aerosol delivery has many potential advantages, including aqueous compatibility, sustained pulmonary release to maintain therapeutic drug levels and facilitated intracellular delivery, particularly to alveolar macrophages ADDIN EN.CITE  [339]. Liposomal aerosols have proven to be non-toxic in acute human and animal studies ADDIN EN.CITE  [340, 341, 342, 343, 344]. These results suggest that drug-liposome aerosols should be more effective for the delivery, deposition and retention of water-insoluble, hydrophobic, lipophilic compounds in contrast to water-soluble compounds ADDIN EN.CITE  [345, 346, 347]. The goal of drug-liposomal aerosol therapy is to maximize delivery and retention while minimizing clearance. 
5.4.3.	Micelles
It is well-known that polymeric micelles are often more stable than surfactant micelles ADDIN EN.CITE  [348]. In general, they are smaller in size than polymeric microspheres and liposomes, their surface properties allow them to escape from macrophage uptake, they are easy to prepare, and they are capable of targeting specific tissues. 
In this field, Jones and Leroux designed beclomethasone dipropionate-loaded polymeric micelles for pulmonary delivery ADDIN EN.CITE  [4]. The concept was developed since polymeric micelles are able to evade the MPS due to their bulky hydrophilic outer shell and sustained drug release. In addition, drug-loaded polymeric micelles are strongly suggested to pass directly to their receptors in epithelial cells through the mucus layer to treat bronchial inflammatory diseases. For these reasons, polymeric micelles are very beneficial in delivering hydrophobic corticosteroids, such as beclomethasone dipropionate, for COPD theory since the inability of such drugs to penetrate the mucus layer to reach the target site is largely the result of treatment failure in the past.
6. Perspectives
Drug NC, able to deliver high doses of therapeutic compounds in specific areas while lowering the exposure of healthy tissues to toxic side-effects, are still an unreached goal. The preparation of such entities is an engineering challenge as several properties must be imparted: stability in biological medium, high drug loading, long circulation in blood (i.v. administration), immune system evasion, and targeting pathological tissues while avoiding healthy ones. Size and surface properties are key elements of biological barrier crossing, at the pulmonary, GI and vascular levels.
Size, hydrodynamic radius and aggregation status are parameters that have been largely explored, but investigations often lack adequate characterization of size and size dispersion ADDIN EN.CITE  [122]. When NC targeting and biodistribution studies are based on inadequately-reported size dispersion or wide size dispersion, the informative value of the studies is limited. Several NC properties are dependant on their environments. The size is one of them as aggregation and opsonisation may change size and size distributions in biological medium. This underlines that NC size is also a surface chemistry problem to be resolved.
The effects of surface charge and surface hydrophobicity have also to be considered in situ. Indeed, once a NC is immersed in biological medium, it is no longer the originally-designed artificial construct. At this point, it is the original construct along with adsorbed proteins (and other substances such as lipids) that profoundly affect its surface characteristics. The properties defined in vitro, before administration, are no longer valid, whether the entry pathway is the upper airways, the GIT or the vascular compartment. For instance, protein coating (either discrete or complete) may not only alter carrier size, but also alter surface charge and hydrophobicity, may turn it into specific-recognition NC (adsorbed protein-mediated recognition), or may change its morphology and surface roughness. 
The modification of generally hydrophobic NC surfaces by PEG has found its way and utility in all type of deliveries, i.v., pulmonary or GI. Despite its widespread use, some concerns regarding its toxicity and interactions with the complement and immune systems have renewed interest in the development of alternatives to pegylation ADDIN EN.CITE  [55, 349]. Regarding surface properties, other challenges ahead are better assessment of polymer architecture effects on surface properties (opsonisation, cellular uptake), and the study and control of surface chemistry heterogeneity at the nanoscale level (as heterogeneity can cause NC failure). 
Some passive NC targeting technologies are currently approved for tumour chemotherapies, and many are either based on liposomes or “nab” technology (both by i.v. administration). But the fraction of dose of these NC accumulated in the tumour still stays low. A similar situation can be found in oral delivery or pulmonary delivery, as NC transport across both epithelium is also weak. Addition of a specific ligand on NC surfaces has been proposed to increase these values. However, no active, targeted drug NC systems have yet been approved, as they fail to show clinically significant improvements over passive targeted systems ADDIN EN.CITE  [93]. 
Clearly, certain factors have been ignored or misinterpreted, and some of them could be related to NC surface properties. Aside from these properties explored (albeit perhaps incompletely), there are many other parameters, ignored or less investigated, that may have their say in the limited success of current NC approaches. For instance, shape, curvature radius, surface roughness, patterning, porosity, density and Young’s modulus of NC may be some parameters worth exploring.
Surfaces with very high curvature radius may suppress protein adsorption, starting with larger proteins ADDIN EN.CITE  [350]. Some authors have identified the topographic effect of surface curvature on protein binding, demonstrating small (30-nm) particles are stabilizing globular protein conformation (albumin, lysozyme), while rod-like proteins are denatured (fibrinogen). It seems possible to favour the binding of some type of proteins by surface design ADDIN EN.CITE  [351, 352]. Surface topography effect is also at work with porous cationic polysaccharides NP showing no change of size and zeta potential or complement activation even after extensive lipid and protein adsorption ADDIN EN.CITE  [353]. Softness and rigidity of particles (combined with size) have an effect on localization to the lung and filtration by the spleen ADDIN EN.CITE  [354, 355]. Young’s modulus of NP has been found to affect endocytosis efficacy and the choice of uptake pathways  ADDIN EN.CITE  [356] with potential consequences for transcytosis efficacy. Moreover, this modulus could change with temperature (above polymer glass transition) or with the state of hydration alteration in polymeric NP.  Finally, it is noteworthy that the development of NC, as sophisticated they may be, should yield fully biocompatible and easily eliminated materials, whether as intact NC or after degradations of their components.

7. Conclusion 
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Fig. (1). Different types of Nanocarriers
(A) Micelle: self assembly of amphiphilic molecules; (B) Liposomes vesicles primarily constituted of a phospholipids bilayer along with another type of lipids (cholesterol or PEG-phospholipids conjugate); (C) Dendrimers are branched symmetric polymeric structures constituted by a core and branches (the dendrons); (E) Polymeric nanoparticles are matrix particle in which the drug is dispersed (here symbolized with black dots); (F) Nanocapsules, are constituted by an core (generally hydrophilic) enclosed in a thin polymeric wall.

Fig. (2). General view of biological barriers to i.v. delivery of drug-loaded NC aimed at the solid tumour interstitium

Fig. (3). PEG NC coverage
(A) “Brush” regimen (high density), (B) “Mushroom” configuration (low density), (C) “PEG loops”: multiblock NP (PLA-PEG-PLA)  ADDIN EN.CITE  [26]or PLA particles with PEG 1400 distearate ADDIN EN.CITE  [37]. PEG chains are presented in black, and the NC core in grey.

Fig. (4). General organisation of blood vessel walls

Fig. (5). Different types of normal capillaries and transport pathways 
(A) Continuous capillary, (B) Fenestrated capillary, (C) Open fenestrated capillary, (D) Sinusoidal capillary. VVO: vesicular-vacuolar organelles; TE channels: transendothelial channels (adapted and modified from [73])

Fig. (6). Glycocalyx structure
Protein backbones appear in black, and glycans in grey. The cell-bound layer is about 60 nm, 
while the absorbed layer is about 500 nm in capillaries. Glycipans and syndecans are the 2 main families of core protein proteoglycans anchored on the plasma membrane. Proteoglycans are associated with glycoaminoglycans (GAG), primarily heparan sulphate (HS), representing 50-90% of GAG along with chondroitin/dermatan sulphate (CS) and hyaluronic acid chains (HA) ADDIN EN.CITE  [81].

Fig. (7). Vascular permeability at the normal continuous capillary level
MP: Macropinosis; CLME: Clathrin-mediated endocytosis; CVME: Caveolae-mediated endocytosis; NCNC: Non-clathrin, non-caveolae pathway; TE: Transendothelial channel; VVO: Vesicular-vacuolar organelle; Lys.: Lysosome; End.: Endosome; Ex. : Exocytosis

Fig. (8). Simplified view of the EPR effect
On the left: situation of normal tissue with continuous capillaries, normal lymphatic drainage, normal ECM and cell organization. NC are excluded from interstitium. On the right: solid tumour with leaky capillary, increased ECM, defective lymphatic drainage and increased IFP. NC are transported by convection and/or diffusing in the tumour interstitium, accumulating mainly in the perivascular region.  

Fig. (9). General structure of the blood-brain barrier
(1) Basement membrane, (2) Endothelial cells (EC), (3) pericyte, (4) astrocytic projection, (5) tight junction, (6) cell nucleus.

Fig. (10). Structures of polymers used in polymeric NP
(a) poly(butylcyanoacrylate), (b) PHDCA polymers, and (c) PEG-PHDCA copolymer.

Fig. (11). Structure GIT barrier: drug and NC transportation pathways. On the left, enterocytes, on the right M cell. A mucus layer is found on the apical side of enterocytes and M cell. (1) Paracellular route, (2) Transcellular route, (3) M-cell phagocytosis

Fig. (12). Structure of alveoli 
Cross-section of an alveolus showing a capillary, alveolar macrophage, surfactant layer, type I and type II cells (adapted and modified from [313])

Fig. (13). Proposed NC transport pathways across alveolar and vascular endothelial cells. Possible translocation mechanisms across the 2 cell layers: (A) Alveolar epithelial tight junctions (paracellular transport), (B) Caveolar receptor-mediated transcytosis, (C) Caveolar trans-endothelial transport, (D) Trans-endothelial channel, (E) Vascular endothelial cell tight junction
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